



Kantonsspital
St.Gallen

Wissenschaftliche Publikationen 2019



Inhaltsverzeichnis

Departement I.....	4
Allgemeine Innere Medizin/Hausarztmedizin.....	4
Endokrinologie/Diabetologie.....	4
Gastroenterologie/Hepatologie.....	5
Infektiologie/Spitalhygiene	7
Kardiologie.....	10
Onkologie/Hämatologie.....	13
Pneumologie/Schlafmedizin	22
Rheumatologie.....	23
Departement II.....	25
Anästhesiologie/Intensivmedizin	25
Klinik für Allgemein-, Viszeral-, Endokrin- und Transplantationschirurgie	25
Klinik für Gefäßschirurgie	26
Frauenklinik	27
Klinik für Urologie.....	29
Departement III.....	33
Augenklinik	33
Hals-Nasen-Ohrenklinik	34
Neurochirurgie	35
Neurologie	36
Departement IV	37
Pathologie.....	37
Radiologie und Nuklearmedizin.....	38
Radio-Onkologie	40
Rechtsmedizin	41
Departement Interdisziplinäre Med. Dienste	43
Zentrale Notfallaufnahme	43
Dermatologie/Allergologie	43
Brustzentrum	45
Muskelzentrum/ALS clinic	46
Institut für Immunbiologie	46
Clinical Trials Unit	48
Palliativzentrum.....	49

Kantonsspital St.Gallen – Publikationen

Am Kantonsspital St.Gallen wird klinische Forschung und translationale Grundlagenforschung auf hohem Niveau betrieben. Die Ergebnisse der Studien und Forschungsprojekte werden an wissenschaftlichen Kongressen präsentiert und in wissenschaftlichen Journalen publiziert. Um die Öffentlichkeit und die Fachwelt über die Forschungsaktivitäten am Kantonsspital St.Gallen zu informieren, werden die Publikationen in der Forschungs- und Studiendatenbank systematisch erfasst und ausgewertet (www.forschung.kssg.ch).

Im Jahr 2019 wurden 416 Publikationen mit Beteiligung von Forschenden des Kantonsspitals St.Gallen veröffentlicht. Von diesen Arbeiten wurden 319 in Journalen mit berechnetem Einflussfaktor (auch Impact Factor genannt) publiziert (Abb. 1). Der Einflussfaktor einer Fachzeitschrift gibt an, wie oft ein Artikel aus dieser Zeitschrift innerhalb von zwei Jahren in anderen Artikeln zitiert wird. Für die Berechnung des mittleren Einflussfaktors der Publikationen des Kantonsspital St.Gallen 2019, wurden Daten des Journal Citation Reports (Clarivate Analytics) aus dem Jahr 2018 verwendet.

Die Analyse des mittleren Einflussfaktors pro Publikation ist deutlich auf 7.2 gestiegen. Das ist das beste Resultat seit der Erfassung dieser Daten. In Abb. 2 sind die Daten der Jahre 2017-2019 gezeigt.

Die Auswertung der Publikationsdaten nach Medizinischen Departementen zeigt (Abb. 3), dass in allen Disziplinen intensiv geforscht und publiziert wird. In Abbildung 3 ist die Publikationstätigkeit der Jahre 2017 – 2019 in den einzelnen Departementen gezeigt. Detaillierte Auswertungen können beim Medizinischen Forschungszentrum (MFZ) angefordert werden. Durch interdisziplinäre Zusammenarbeiten sind die Summen der Publikationen höher als jene aus Abb. 1 und 2.




Abb.1. Anzahl der Publikationen in Journalen mit oder ohne Einflussfaktor in den Jahren 2017 – 2019




Abb.2. Mittlere Qualität der Publikationen gemessen als durchschnittlicher Einflussfaktor (EF) pro Veröffentlichung




Abb. 3. Publikationsstatistik in den Departementen I-IV und IMD in den Jahren 2017 – 2019

Die Publikationen wurden direkt aus der Forschungs- und Studiendatenbank des KSSG extrahiert (www.forschung.kssg.ch). Für die Vollständigkeit und Richtigkeit der Publikationen in der Datenbank tragen die Fachbereiche die Verantwortung. Durch Anklicken des Bereichs/Instituts wird man direkt auf die Publikationen in der Datenbank verlinkt.

Departement I

Allgemeine Innere Medizin/Hausarztmedizin

Wissenschaftliche Artikel

1. Baerlocher L. Brain abscess caused by Cladophialophora bantiana: Total remission after full resection and short-course Voriconazole treatment. *Med Mycol Case Rep* 2019; 2019 Mar; 23: 43–45.:.
2. Brändle M. Polyglobulie bei Missbrauch von androgenen anabolen Steroiden : Was hat «Das Schwarze Buch» mit Aderlass zu tun. *Swiss Med Forum* 2019; 19:655-658.
3. Hersberger L, Bargetzi L, Bargetzi A, Trbolet P, Fehr R, Baechli V, Geiser M, Deiss M, Gomes F, Kutz A, Kägi-Braun N, Hoess C, Pavlicek V, Schmid S, Bilz S, Sigrist S, Brändle M, Benz C, Henzen C, Nigg M, Thomann R, Brand C, Rutishauser J, Aujesky D, Rodondi N, Donzé J, Stanga Z, Mueller B, Schuetz P. Nutritional risk screening (NRS 2002) is a strong and modifiable predictor risk score for short-term and long-term clinical outcomes: secondary analysis of a prospective randomised trial. *Clin Nutr* 2019;.
4. Koster M, Ritter S, Brändle M. [Rapid Resolution of Symptomatic Hypercalcaemia]. *Praxis (Bern 1994)* 2019; 108:495-498.
5. Merker M, Amsler A, Pereira R, Bolliger R, Trbolet P, Braun N, Hoess C, Pavlicek V, Bilz S, Sigrist S, Brändle M, Henzen C, Thomann R, Rutishauser J, Aujesky D, Rodondi N, Donzé J, Stanga Z, Mueller B, Schuetz P. Vitamin D deficiency is highly prevalent in malnourished inpatients and associated with higher mortality: A prospective cohort study. *Medicine (Baltimore)* 2019; 98:e18113.
6. Schuetz P, Fehr R, Baechli V, Geiser M, Deiss M, Gomes F, Kutz A, Trbolet P, Bregenzer T, Braun N, Hoess C, Pavlicek V, Schmid S, Bilz S, Sigrist S, Brändle M, Benz C, Henzen C, Mattmann S, Thomann R, Brand C, Rutishauser J, Aujesky D, Rodondi N, Donzé J, Stanga Z, Mueller B. Individualised nutritional support in medical inpatients at nutritional risk: a randomised clinical trial. *Lancet* 2019; 393:2312-2321.
7. Wiesli P, Pavlicek V, Brändle M, Pfammatter T, Perren A, Schmid C. Distinct mechanisms of hypoglycaemia in patients with somatostatin-secreting neuroendocrine tumours. *Endocrinol Diabetes Metab* 2019; 2:e00083.

Endokrinologie/Diabetologie

Wissenschaftliche Artikel

1. Brändle M. Polyglobulie bei Missbrauch von androgenen anabolen Steroiden : Was hat «Das Schwarze Buch» mit Aderlass zu tun. *Swiss Med Forum* 2019; 19:655-658.
2. Drescher T. The prevalence of retinopathy in patients with type 1 diabetes treated with education-based intensified insulin therapy and its association with parameters of glucose control. *Diabetes Rec Clin Pract* 2019; 148:..
3. Hersberger L, Bargetzi L, Bargetzi A, Trbolet P, Fehr R, Baechli V, Geiser M, Deiss M, Gomes F, Kutz A, Kägi-Braun N, Hoess C, Pavlicek V, Schmid S, Bilz S, Sigrist S, Brändle M, Benz C, Henzen C, Nigg M, Thomann R, Brand C, Rutishauser J, Aujesky D, Rodondi N, Donzé J, Stanga Z, Mueller B, Schuetz P. Nutritional risk screening (NRS 2002) is a strong and modifiable predictor risk score for short-term and long-term clinical outcomes: secondary analysis of a prospective randomised trial. *Clin Nutr* 2019;.

prospective randomised trial. Clin Nutr 2019;.

4. Koster M, Ritter S, Brändle M. [Rapid Resolution of Symptomatic Hypercalcaemia]. Praxis (Bern 1994) 2019; 108:495-498.
5. Merker M, Amsler A, Pereira R, Bolliger R, Tribolet P, Braun N, Hoess C, Pavlicek V, Bilz S, Sigrist S, Brändle M, Henzen C, Thomann R, Rutishauser J, Aujesky D, Rodondi N, Donzé J, Stanga Z, Mueller B, Schuetz P. Vitamin D deficiency is highly prevalent in malnourished inpatients and associated with higher mortality: A prospective cohort study. Medicine (Baltimore) 2019; 98:e18113.
6. Schuetz P, Fehr R, Baechli V, Geiser M, Deiss M, Gomes F, Kutz A, Tribolet P, Bregenzer T, Braun N, Hoess C, Pavlicek V, Schmid S, Bilz S, Sigrist S, Brändle M, Benz C, Henzen C, Mattmann S, Thomann R, Brand C, Rutishauser J, Aujesky D, Rodondi N, Donzé J, Stanga Z, Mueller B. Individualised nutritional support in medical inpatients at nutritional risk: a randomised clinical trial. Lancet 2019; 393:2312-2321.
7. Wiesli P, Pavlicek V, Brändle M, Pfammatter T, Perren A, Schmid C. Distinct mechanisms of hypoglycaemia in patients with somatostatin-secreting neuroendocrine tumours. Endocrinol Diabetes Metab 2019; 2:e00083.
8. Zulewski H, Giovanella L, Bilz S, Christ E, Haldemann A, Steinert H, Weidner S, Oertli D, Triponez F, Clerici T, Minder A, Dettmer M, Komminoth P. Multidisciplinary approach for risk-oriented treatment of low-risk papillary thyroid cancer in Switzerland. Swiss Med Wkly 2019; 149:w14700.

Gastroenterologie/Hepatologie

Wissenschaftliche Artikel

1. About F, Bibert S, Jouanguy E, Nalpas B, Lorenzo L, Rattina V, Zarhrate M, Hanein S, Munteanu M, Müllhaupt B, Semela D, Semmo N, Casanova J L, Theodorou I, Sultanik P, Poynard T, Pol S, Bochud P Y, Cobat A, Abel L, Swiss Hepatitis C Cohort Study Group , French ANRS HC EP 26 Genoscan Study Group . Identification of an Endoglin Variant Associated With HCV-Related Liver Fibrosis Progression by Next-Generation Sequencing. Front Genet 2019; 10:1024.
2. Baumeler S, Jochum W, Neuweiler J, Bergamin I, Semela D. Controlled attenuation parameter for the assessment of liver steatosis in comparison with liver histology: a single-centre real life experience. Swiss Med Wkly 2019; 149:w20077.
3. Bertisch B, Brezzi M, Negro F, Müllhaupt B, Ottiger C, Künzler-Heule P, Schmid P, Giudici F, Clerc O, Moriggia A, Roelens M, Marinucci F, Zehnder C, Moradpour D, Keiser O, Swiss Hepatitis C Cohort Study . Very low hepatitis C viral loads in treatment-naïve persons: do they compromise hepatitis C virus antigen testing. Clin Infect Dis 2019;.
4. Brenig R, Pop O, Triantafyllou E, Geng A, Singanayagam A, Perez Shibayama C, Besse L, Cupovic J, Künzler-Heule P, Boldanova T, Brand S, Semela D, Duong F H, Weston C J, Ludewig B, Heim M H, Wendon J, Antoniades C G, Bernsmeier C. Expression of AXL receptor tyrosine kinase relates to monocyte dysfunction and severity of cirrhosis. Life Sci Alliance 2019; 3:.
5. Brezzi M, Bertisch B, Roelens M, Moradpour D, Terzioli Beretta-Piccoli B, Semmo N, Müllhaupt B, Semela D, Negro F, Keiser O, Swiss Hepatitis C Cohort Study . Impact of geographic origin on access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study. PLoS ONE 2019; 14:e0218706.
6. Chmiel C, Senn O, Hasler S, Rosemann T, Rogler G, Zahnd N, Tandjung R, Scherz N, Sulz M, Vavricka S. Can the CalproQuest predict a positive Calprotectin test? A prospective diagnostic study. PLoS ONE 2019; 14:e0224961.

7. Cottrell A M, Schneider M P, Goonewardene S, Yuan Y, Baranowski A P, Engeler D S, Borovicka J, Dinis-Oliveira P, Elneil S, Hughes J, Messelink B J, de C Williams A C. Benefits and Harms of Electrical Neuromodulation for Chronic Pelvic Pain: A Systematic Review. *Eur Urol Focus* 2019;.
8. De Gottardi A, Rautou P E, Schouten J, Rubbia-Brandt L, Leebeek F, Trebicka J, Murad S D, Vilgrain V, Hernandez-Gea V, Nery F, Plessier A, Berzigotti A, Bioulac-Sage P, Primignani M, Semela D, Elkrief L, Bedossa P, Valla D, Garcia-Pagan J C, VALDIG group . Porto-sinusoidal vascular disease: proposal and description of a novel entity. *Lancet Gastroenterol Hepatol* 2019; 4:399-411.
9. Dietz J, Spengler U, Müllhaupt B, Schulze Zur Wiesch J, Piecha F, Mauss S, Seegers B, Hinrichsen H, Antoni C, Wietzke-Braun P, Peiffer K H, Berger A, Matschenz K, Buggisch P, Backhus J, Ziser E, Boettler T, Neumann-Haefelin C, Semela D, Stauber R, Berg T, Berg C, Zeuzem S, Vermehren J, Sarrazin C, European HCV Resistance Study Group . Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections. *Clin Gastroenterol Hepatol* 2019;.
10. Dimova I, Karthik S, Makanya A, Hlushchuk R, Semela D, Volarevic V, Djonov V. SDF-1/CXCR4 signalling is involved in blood vessel growth and remodelling by intussusception. *J Cell Mol Med* 2019; 23:3916-3926.
11. Efe C, Taşçilar K, Henriksson I, Lytvyyak E, Alalkim F, Trivedi H, Eren F, Eliasson J, Beretta-Piccoli B T, Fischer J, Çalışkan A R, Chayanupatkul M, Coppo C, Ytting H, Purnak T, Muratori L, Werner M, Muratori P, Rorsman F, Önnerhag K, Günşar F, Nilsson E, Heurgué-Berlot A, Güzelbulut F, Demir N, Gönen C, Semela D, Aladağ M, Kiyici M, Schiano T D, Montano-Loza A J, Berg T, Ozaslan E, Yoshida E M, Bonder A, Marschall H U, Wahlin S. Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis. *Am J Gastroenterol* 2019; 114:1101-1108.
12. Goossens N, Bellentani S, Cerny A, Dufour J F, Jornayvaz F R, Mertens J, Moriggia A, Muellhaupt B, Negro F, Razavi H, Semela D, Estes C. Nonalcoholic fatty liver disease burden - Switzerland 2018-2030. *Swiss Med Wkly* 2019; 149:w20152.
13. Hampel B, Kusejko K, Kouyos R D, Böni J, Flepp M, Stöckle M, Conen A, Béguelin C, Künzler-Heule P, Nicca D, Schmidt A J, Nguyen H, Delaloye J, Rougemont M, Bernasconi E, Rauch A, Günthard H F, Braun D L, Fehr J, Swiss HIV Cohort Study group . Chemsex drugs on the rise: a longitudinal analysis of the Swiss HIV Cohort Study from 2007 to 2017. *HIV Med* 2019;.
14. Kocher A, Simon M, Dwyer A A, Villiger P M, Künzler-Heule P, De Geest S, Berben L, Nicca D. Developing a rare disease chronic care model: Management of systemic sclerosis (MANOSS) study protocol. *J Adv Nurs* 2019;.
15. Künzler-Heule P, Engberg S, Battegay M, Schmidt A J, Fierz K, Nguyen H, Kocher A, Nöstlinger C, Hampel B, Stöckle M, Béguelin C, Delaloye J, Schmid P, Flepp M, Rougement M, Braun D L, Fehr J, Nicca D, Swiss HIV Cohort Study (SHCS) . Screening HIV-positive men who have sex with men for hepatitis C re-infection risk: is a single question on condom-use enough? A sensitivity analysis. *BMC Infect Dis* 2019; 19:821.
16. Sahli R, Fraga M, Abbühl D, Moradpour D, Gouttenoire J. Rabbit HEV in immunosuppressed patients with hepatitis E acquired in Switzerland. *J Hepatol* 2019;.
17. Sawatzki M, Meyenberger C, Brand S, Semela D. Contrast-enhanced ultrasound (CEUS) has excellent diagnostic accuracy in differentiating focal liver lesions: results from a Swiss tertiary gastroenterological centre. *Swiss Med Wkly* 2019; 149:w20087.
18. Seidl S, Bergamin I, Boggian K, Meuthen T. Hepatosplenische Schistosomiasis. *Swiss Medical Forum* 2019; 19:824-826.
19. Terziroli Beretta-Piccoli B, Di Bartolomeo C, Deleonardi G, Grondona A G, Silvestri T, Tesei C,

Melidona L, Cerny A, Mertens J, Semmo N, Semela D, Moradpour D, Mieli-Vergani G, Vergani D, Muratori L, Swiss Hepatitis C Cohort Study . Autoimmune liver serology before and after successful treatment of chronic hepatitis C by direct acting antiviral agents. *J Autoimmun* 2019; 102:89-95.

Infektiologie/Spitalhygiene

Wissenschaftliche Artikel

1. Albrich W, Rassouli F, Waldeck F, Berger C, Baty F. Influence of Older Age and Other Risk Factors on Pneumonia Hospitalization in Switzerland in the Pneumococcal Vaccine Era. *Front Med (Lausanne)* 2019; 6:286.
2. Asner S A, Agyeman P K A, Gradoux E, Posfay-Barbe K M, Heininger U, Giannoni E, Crisinel P A, Stocker M, Bernhard-Stirnemann S, Niederer-Lohr A, Kahlert C R, Hasters P, Relly C, Baer W, Aebi C, Schlapbach L J, Berger C, Swiss Paediatric Sepsis Study group . Burden of *Streptococcus pneumoniae* sepsis in children after introduction of pneumococcal conjugate vaccines - a prospective population-based cohort study. *Clin Infect Dis* 2019;.
3. Bertisch B, Brezzi M, Negro F, Müllhaupt B, Ottiger C, Künzler-Heule P, Schmid P, Giudici F, Clerc O, Moriggia A, Roelens M, Marinucci F, Zehnder C, Moradpour D, Keiser O, Swiss Hepatitis C Cohort Study . Very low hepatitis C viral loads in treatment-naïve persons: do they compromise hepatitis C virus antigen testing. *Clin Infect Dis* 2019;.
4. Betschart P, Zumstein V, Buhmann M, Albrich W, Nolte O, Güsewell S, Schmid H P, Ren Q, Abt D. Influence of biofilms on morbidity associated with short-term indwelling ureteral stents: a prospective observational study. *World J Urol* 2019;1703-11.
5. Boggian K. Behandlung der Streptokokken-Angina. SWISS MEDICAL FORUM – SCHWEIZERISCHES MEDIZIN-FORUM 2019; 2019;19(29–30):481–488:.
6. Buhmann M T, Abt D, Nolte O, Neu T R, Strempel S, Albrich W, Betschart P, Zumstein V, Neels A, Maniura-Weber K, Ren Q. Encrustations on ureteral stents from patients without urinary tract infection reveal distinct urotypes and a low bacterial load. *Microbiome* 2019; 7:60.
7. Burgener A V, Bantug G R, Meyer B J, Higgins R, Ghosh A, Bignucolo O, Ma E H, Loeliger J, Unterstab G, Geigges M, Steiner R, Enamorado M, Ivanek R, Hunziker D, Schmidt A, Müller-Durovic B, Grählert J, Epple R, Dimeloe S, Lötscher J, Sauder U, Ebnöther M, Burger B, Heijnen I, Martínez-Cano S, Cantoni N, Brücker R, Kahlert C R, Sancho D, Jones R G, Navarini A, Recher M, Hess C. SDHA gain-of-function engages inflammatory mitochondrial retrograde signaling via KEAP1-Nrf2. *Nat Immunol* 2019; 20:1311-1321.
8. Carlisle L A, Turk T, Kusejko K, Metzner K J, Leemann C, Schenkel C, Bachmann N, Posada S, Beerenwinkel N, Böni J, Yerly S, Klimkait T, Perreau M, Braun D L, Rauch A, Calmy A, Cavassini M, Battegay M, Vernazza P, Bernasconi E, Günthard H F, Kouyos R D, Swiss HIV Cohort Study . Viral diversity from next-generation sequencing of HIV-1 samples provides precise estimates of infection recency and time since infection. *J Infect Dis* 2019;.
9. Compagno F, Naegele K, Kahlert C R, Hösli I, Aebi-Popp K, Martinez de Tejada B, Paioni P, Yerly S, Böni J, Battegay M, Rudin C, Hirsch H H, Swiss HIV Cohort Study . The rate of mother-to-child transmission of antiretroviral drug-resistant HIV strains is low in the Swiss Mother and Child HIV Cohort Study. *Swiss Med Wkly* 2019; 149:w20059.
10. Fehr M, Cathomas G, Graber A, Markert E, Gaus E, Boggian K. Multi-fungal sepsis and mucormycosis of the central nervous system in a patient treated with ibrutinib, a case report and review of the literature. *Med Mycol Case Rep* 2019; 27:14-16.
11. Frischknecht M, Meier A, Mani B, Joerg L, Kim O C H, Boggian K, Strahm C. Tularemia: an

experience of 13 cases including a rare myocarditis in a referral center in Eastern Switzerland (Central Europe) and a review of the literature. Infection 2019;.

12. Fulchini R, Albrich W, Kronenberg A, Egli A, Kahlert C R, Schlegel M, Kohler P. Antibiotic-resistant pathogens in different patient settings and identification of surveillance gaps in Switzerland - a systematic review. Epidemiol Infect 2019; 147:e259.
13. Hartnell F, Brown A, Capone S, Kopycinski J, Bliss C, Makvandi-Nejad S, Swadling L, Ghaffari E, Cicconi P, Del Sorbo M, Sbrocchi R, Esposito I, Vassilev V, Marriott P, Gardiner C M, Bannan C, Bergin C, Hoffmann M, Turner B, Nicosia A, Folgori A, Hanke T, Barnes E, Dorrell L. A Novel Vaccine Strategy Employing Serologically Different Chimpanzee Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection. Front Immunol 2019; 9:3175.
14. Jamal A J, Garcia-Jeldes F, Baqi M, Borgia S, Johnstone J, Katz K, Kohler P, Muller M P, McGeer A J, CPE Investigators of the Toronto Invasive Bacterial Diseases Network . Infection prevention and control practices related to carbapenemase-producing Enterobacteriaceae (CPE) in acute-care hospitals in Ontario, Canada. Infect Control Hosp Epidemiol 2019; 40:1006-1012.
15. Jiang L, McGeer A, McNeil S, Katz K, Loeb M, Muller M P, Simor A, Powis J, Kohler P, Di Bella J M, Coleman B L, Canadian Healthcare Worker Study Group . Which healthcare workers work with acute respiratory illness? Evidence from Canadian acute-care hospitals during 4 influenza seasons: 2010-2011 to 2013-2014. Infect Control Hosp Epidemiol 2019; 40:889-896.
16. Künzler-Heule P, Engberg S, Battegay M, Schmidt A J, Fierz K, Nguyen H, Kocher A, Nöstlinger C, Hampel B, Stöckle M, Béguelin C, Delaloye J, Schmid P, Flepp M, Rougement M, Braun D L, Fehr J, Nicca D, Swiss HIV Cohort Study (SHCS) . Screening HIV-positive men who have sex with men for hepatitis C re-infection risk: is a single question on condom-use enough? A sensitivity analysis. BMC Infect Dis 2019; 19:821.
17. Kusejko K, Salazar-Vizcaya L, Braun D L, Tarr P E, Bernasconi E, Doco-Lecompte T, Cavassini M, Schmid P, Du Pasquier R, Hauser C, Günthard H F, Kouyos R D, Swiss HIV Cohort Study . Self-reported neurocognitive impairment in people living with HIV: Characterizing clusters of patients with similar changes in self-reported neurocognitive impairment 2013-2017 in the Swiss HIV Cohort Study. Clin Infect Dis 2019;.
18. Lotz H, Strahm C, Zdravkovic V, Jost B, Albrich W. Septic arthritis due to streptococci and enterococci in native joints. Infection 2019; 47:761-770.
19. Metral M, Nadin I, Locatelli I, Tarr P E, Calmy A, Kovari H, Brugger P, Cusini A, Gutbrod K, Abbühl D, Schwind M, Kunze U, Di Benedetto C, Pignatti R, Du Pasquier R, Darling K, Cavassini M, Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study group, Swiss HIV Cohort Study . How helpful are the European AIDS Clinical Society cognitive screening questions in predicting cognitive impairment in an aging, well-treated HIV-positive population. HIV Med 2019;.
20. Notter J, Bregenzer A, Vernazza P, Kahlert C R. Nevirapine in HIV maintenance therapy - can "old drugs" survive in current HIV management. Swiss Med Wkly 2019; 149:w20053.
21. Olearo F, Nguyen H, Bonnet F, Yerly S, Wandeler G, Stoeckle M, Cavassini M, Scherrer A, Costagliola D, Schmid P, Günthard H F, Bernasconi E, Boeni J, D'arminio Monforte A, Zazzi M, Rossetti B, Neau D, Bellecave P, Rijnders B, Reiss P, Wit F, Kouyos R, Calmy A. Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients. Open Forum Infect Dis 2019; 6:ofz330.
22. Olearo F, Nguyen H, Bonnet F, Yerly S, Wandeler G, Stoeckle M, Cavassini M, Scherrer A, Costagliola D, Schmid P, Günthard H F, Bernasconi E, Boeni J, D'arminio Monforte A, Zazzi M, Rossetti B, Neau D, Bellecave P, Rijnders B, Reiss P, Wit F, Kouyos R, Calmy A. Corrigendum to: Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients. Open Forum Infect Dis 2019; 6:ofz500.

23. Ottink K D, Strahm C, Muller-Kobold A, Sendi P, Wouthuyzen-Bakker M. Factors to Consider When Assessing the Diagnostic Accuracy of Synovial Leukocyte Count in Periprosthetic Joint Infection. *J Bone Jt Infect* 2019; 4:167-173.
24. Petrone L, Albrich W C, Tamarozzi F, Frischknecht M, Gomez-Morales M A, Teggi A, Hoffmann M, Goletti D. Species-specificity preliminary evaluation of an IL-4 based test for the differential diagnosis of human echinococcosis. *Parasite Immunol* 2019;e12695.
25. Rodger A J, Cambiano V, Bruun T, Vernazza P, Collins S, Degen O, Corbelli G M, Estrada V, Geretti A M, Beloukas A, Raben D, Coll P, Antinori A, Nwokolo N, Rieger A, Prins J M, Blaxhult A, Weber R, Van Eeden A, Brockmeyer N H, Clarke A, Del Romero Guerrero J, Raffi F, Bogner J R, Wandeler G, Gerstoft J, Gutiérrez F, Brinkman K, Kitchen M, Ostergaard L, Leon A, Ristola M, Jessen H, Stellbrink H J, Phillips A N, Lundgren J, PARTNER Study Group . Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. *Lancet* 2019;:
26. Ruffieux Y, Lemsalu L, Aebi-Popp K, Calmy A, Cavassini M, Fux C A, Günthard H F, Marzolini C, Scherrer A, Vernazza P, Keiser O, Egger M, Swiss HIV Cohort Study and the Swiss National Cohort . Mortality from suicide among people living with HIV and the general Swiss population: 1988-2017. *J Int AIDS Soc* 2019; 22:e25339.
27. Rusch U, Robbins S, Razavi H, Vernazza P, Blach S, Bruggmann P, Müllhaupt B, Negro F, Semela D. Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regions. *Swiss Med Wkly* 2019; 149:w14694.
28. Santos G M A, Locatelli I, Métral M, Calmy A, Lecompte T D, Nadin I, Hauser C, Cusini A, Hasse B, Kovari H, Tarr P, Stoeckle M, Fux C, Di Benedetto C, Schmid P, Darling K E A, Du Pasquier R, Cavassini M, Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) Study Group . Cross-Sectional and Cumulative Longitudinal Central Nervous System Penetration Effectiveness Scores Are Not Associated With Neurocognitive Impairment in a Well Treated Aging Human Immunodeficiency Virus-Positive Population in Switzerland. *Open Forum Infect Dis* 2019; 6:ofz277.
29. Seidl S, Bergamin I, Boggian K, Meuthen T. Hepatosplenische Schistosomiasis. *Swiss Medical Forum* 2019; 19:824-826.
30. Seiffert S N, Wüthrich D, Gerth Y, Egli A, Kohler P, Nolte O. First clinical case of KPC-3-producing in Europe. *New Microbes New Infect* 2019; 29:100516.
31. Seth-Smith H M B, Casanova C, Sommerstein R, Meinel D M, Abdelbary M M H, Blanc D S, Droz S, Führer U, Lienhard R, Lang C, Dubuis O, Schlegel M, Widmer A, Keller P M, Marschall J, Egli A. Phenotypic and Genomic Analyses of Burkholderia stabilis Clinical Contamination, Switzerland. *Emerging Infect Dis* 2019; 25:1084-1092.
32. Young J, Scherrer A U, Calmy A, Tarr P E, Bernasconi E, Cavassini M, Hachfeld A, Vernazza P, Günthard H F, Bucher H C, Swiss HIV Cohort Study . The comparative effectiveness of NRTI-sparing dual regimens in emulated trials using observational data from the Swiss HIV Cohort Study. *Antivir Ther (Lond)* 2019;:
33. Zumstein V, Betschart P, Buhmann M T, Albrich W, Nolte O, Güsewell S, Engeler D S, Schmid H P, Ren Q, Abt D. Detection of microbial colonization of the urinary tract of patients prior to secondary ureterorenoscopy is highly variable between different types of assessment: results of a prospective observational study. *Biofouling* 2019;1-10.

Kardiologie

Wissenschaftliche Artikel

1. Asatryan B, Schaller A, Seiler J, Servatius H, Noti F, Baldinger S H, Tanner H, Roten L, Dillier R, Lam A, Haeberlin A, Conte G, Saguner A M, Müller S A, Duru F, Auricchio A, Ammann P, Sticherling C, Burri H, Reichlin T, Wilhelm M, Medeiros-Domingo A. Usefulness of Genetic Testing in Sudden Cardiac Arrest Survivors With or Without Previous Clinical Evidence of Heart Disease. *Am J Cardiol* 2019; 123:2031-2038.
2. Beale A L, Nanayakkara S, Segal L, Mariani J A, Maeder M T, van Empel V, Vizi D, Evans S, Lam C S P, Kaye D M. Sex Differences in Heart Failure With Preserved Ejection Fraction Pathophysiology: A Detailed Invasive Hemodynamic and Echocardiographic Analysis. *JACC Heart Fail* 2019; 7:239-249.
3. Blum S, Aeschbacher S, Meyre P, Zwimpfer L, Reichlin T, Beer J H, Ammann P, Auricchio A, Kobza R, Erne P, Moschovitis G, di Valentino M, Shah D, Schläpfer J, Henz S, Meyer-Zürn C, Roten L, Schwenkglenks M, Sticherling C, Kühne M, Osswald S, Conen D, Swiss-AF Investigators . Incidence and Predictors of Atrial Fibrillation Progression. *J Am Heart Assoc* 2019; 8:e012554.
4. Conen D, Rodondi N, Müller A, Beer J H, Ammann P, Moschovitis G, Auricchio A, Hayoz D, Kobza R, Shah D, Novak J, Schläpfer J, di Valentino M, Aeschbacher S, Blum S, Meyre P, Sticherling C, Bonati L H, Ehret G, Moutzouri E, Fischer U, Monsch A U, Stippich C, Wuerfel J, Sinnecker T, Coslovsky M, Schwenkglenks M, Kühne M, Osswald S, Swiss-AF Study Investigators . Relationships of Overt and Silent Brain Lesions With Cognitive Function in Patients With Atrial Fibrillation. *J Am Coll Cardiol* 2019; 73:989-999.
5. Conte G, Belhassen B, Lambiase P, Ciccone G, de Asmundis C, Arbelo E, Schaer B, Frontera A, Burri H, Calo' L, Letsas K P, Leyva F, Porter B, Saenen J, Zacà V, Berne P, Ammann P, Zardini M, Luani B, Rordorf R, Sarquella Brugada G, Medeiros-Domingo A, Geller J C, de Potter T, Stokke M K, Márquez M F, Michowitz Y, Honarbakhsh S, Conti M, Sticherling C, Martino A, Zegard A, Özkal T, Caputo M L, Regoli F, Braun-Dullaeus R C, Notarangelo F, Moccetti T, Casu G, Rinaldi C A, Levinstein M, Haugaa K H, Derval N, Klersy C, Curti M, Pappone C, Heidbuchel H, Brugada J, Haïssaguerre M, Brugada P, Auricchio A. Out-of-hospital cardiac arrest due to idiopathic ventricular fibrillation in patients with normal electrocardiograms: results from a multicentre long-term registry. *Europace* 2019; 21:1670-1677.
6. Fehr N, Witassek F, Radovanovic D, Erne P, Puhan M, Rickli H. Antidepressant prescription in acute myocardial infarction is associated with increased mortality 1 year after discharge. *Eur J Intern Med* 2019; 61:75-80.
7. Frey S M, Sticherling C, Altmann D, Brenner R, Kühne M, Ammann P, Coslovsky M, Osswald S, Schaer B. The Medtronic Sprint Fidelis® lead history revisited-Extended follow-up of passive leads. *Pacing Clin Electrophysiol* 2019;.
8. Gil Cruz C, Perez Shibayama C, De Martin A, Ronchi F, van der Borgh K, Niederer R, Onder L, Lütge M, Novkovic M, Nindl V, Ramos G, Arnoldini M, Slack E M C, Boivin-Jahns V, Jahns R, Wyss M, Mooser C, Lambrecht B N, Maeder M T, Rickli H, Flatz L, Eriksson U, Geuking M B, McCoy K D, Ludewig B. Microbiota-derived peptide mimics drive lethal inflammatory cardiomyopathy. *Science* 2019; 366:881-886.
9. Hermann M, Witassek F, Erne P, Eberli F, Muller O, Roffi M, Maggiorini M, Radovanovic D, Rickli H, AMIS Plus Investigators . Impact of cardiac rehabilitation participation on patient-reported lifestyle changes one year after myocardial infarction. *Eur J Prev Cardiol* 2019;2047487319895429.
10. Hunziker L, Radovanovic D, Jeger R, Pedrazzini G, Cuculi F, Urban P, Erne P, Rickli H, Pilgrim T, AMIS Plus Registry Investigators are listed in alphabetic order with the names of the local

principal investigators . Twenty-Year Trends in the Incidence and Outcome of Cardiogenic Shock in AMIS Plus Registry. *Circ Cardiovasc Interv* 2019; 12:e007293.

11. Iglesias J F, Heg D, Roffi M, Tüller D, Lanz J, Rigamonti F, Muller O, Moarof I, Cook S, Weilenmann D, Kaiser C, Cuculi F, Valgimigli M, Jüni P, Windecker S, Pilgrim T. Five-Year Outcomes in Patients With Diabetes Mellitus Treated With Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents. *J Am Heart Assoc* 2019; 8:e013607.
12. Iglesias J F, Heg D, Roffi M, Tüller D, Noble S, Muller O, Moarof I, Cook S, Weilenmann D, Kaiser C, Cuculi F, Häner J, Jüni P, Windecker S, Pilgrim T. Long-Term Effect of Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents in Patients With Small Vessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the BIOSCIENCE Randomized Trial. *Circ Cardiovasc Interv* 2019; 12:e008024.
13. Iglesias J F, Muller O, Heg D, Roffi M, Kurz D J, Moarof I, Weilenmann D, Kaiser C, Tapponnier M, Stortecky S, Losdat S, Eeckhout E, Valgimigli M, Odutayo A, Zwahlen M, Jüni P, Windecker S, Pilgrim T. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial. *Lancet* 2019; 394:1243-1253.
14. Jeger R V, Pfisterer M, Vogt D R, Galatius S, Abildgaard U, Naber C, Alber H, Eberli F, Kurz D J, Pedrazzini G, Vuilliomenet A, Weilenmann D, Rickli H, Hansen K W, Rickenbacher P, Conen D, Müller C, Osswald S, Gilgen N, Kaiser C. Competing risks of major bleeding and thrombotic events with prasugrel-based dual antiplatelet therapy after stent implantation - An observational analysis from BASKET-PROVE II. *PLoS ONE* 2019; 14:e0210821.
15. Kozuharov N, Goudev A, Flores D, Maeder M T, Walter J, Shrestha S, Gualandro D M, de Oliveira Junior M T, Sabti Z, Müller B, Noveanu M, Socrates T, Ziller R, Bayés-Genís A, Sionis A, Simon P, Michou E, Gujer S, Gori T, Wenzel P, Pfister O, Conen D, Kapos I, Kobza R, Rickli H, Breidthardt T, Münz T, Erne P, Mueller C, GALACTIC Investigators. Effect of a Strategy of Comprehensive Vasodilation vs Usual Care on Mortality and Heart Failure Rehospitalization Among Patients With Acute Heart Failure: The GALACTIC Randomized Clinical Trial. *JAMA* 2019; 322:2292-2302.
16. Metral M, Nadin I, Locatelli I, Tarr P E, Calmy A, Kovari H, Brugger P, Cusini A, Gutbrod K, Abbühl D, Schwind M, Kunze U, Di Benedetto C, Pignatti R, Du Pasquier R, Darling K, Cavassini M, Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study group, Swiss HIV Cohort Study . How helpful are the European AIDS Clinical Society cognitive screening questions in predicting cognitive impairment in an aging, well-treated HIV-positive population. *HIV Med* 2019;.
17. Neurauter E, Leschka S, Wildermuth S, Ehl N, Jörg L, Rickli H, Maeder M T. Use of coronary computed tomography angiography in clinical practice - single centre experience in Switzerland in light of current recommendations based on pretest probability considerations. *Swiss Med Wkly* 2019; 149:w20010.
18. Pozzoli A, Taramasso M, Haager P K, Miura M, Gülmez G, Lin S I, Gavazzoni M, Rickli H, Maisano F. Clinical Outcomes in Patients with Severe Aortic Valve Stenosis Treated with a Portico Transcatheter Aortic Valve System. *Surg Technol Int* 2019; 34:331-338.
19. Regoli F, Graf D, Schaer B, Duru F, Ammann P, Stefano L M d S, Naegli B, Burri H, Zbinden R, Krasniqi N, Fromer M, 4P Study Group . Arrhythmic episodes in patients implanted with a cardioverter-defibrillator - results from the Prospective Study on Predictive Quality with Preferencing PainFree ATP therapies (4P). *BMC Cardiovasc Disord* 2019; 19:146.
20. Roberto M, Radovanovic D, de Benedetti E, Biasco L, Halasz G, Quagliana A, Erne P, Rickli H, Pedrazzini G, Moccetti M. Temporal trends in latecomer STEMI patients: insights from the AMIS

Plus registry 1997-2017. Rev Esp Cardiol (Engl Ed) 2019;.

21. Sahli R, Fraga M, Abbühl D, Moradpour D, Gouttenoire J. Rabbit HEV in immunosuppressed patients with hepatitis E acquired in Switzerland. J Hepatol 2019;.
22. Schiefer R, Rickli H, Neurauter E, Buser M, Weilenmann D, Maeder M T. Non-invasive assessment prior to invasive coronary angiography in routine clinical practice in Switzerland - Is it according to the guidelines. PLoS ONE 2019; 14:e0222137.
23. Simonavičius J, Sanders van-Wijk S, Rickenbacher P, Maeder M T, Pfister O, Kaufmann B A, Pfisterer M, Čelutkienė J, Puronaitė R, Knackstedt C, van Empel V, Brunner-La Rocca H P. Prognostic Significance of Longitudinal Clinical Congestion Pattern in Chronic Heart Failure: Insights From TIME-CHF Trial. Am J Med 2019; 132:e679-e692.
24. Wischnewsky M B, Candreva A, Bacchi B, Cammann V L, Kato K, Szawan K A, Gili S, D'Ascenzo F, Dichtl W, Citro R, Bossone E, Neuhaus M, Franke J, Sorici-Barb I, Jaguszewski M, Noutsias M, Knorr M, Heiner S, Burgdorf C, Kherad B, Tschöpe C, Sarcon A, Shinbane J, Rajan L, Michels G, Pfister R, Cuneo A, Jacobshagen C, Karakas M, Koenig W, Pott A, Meyer P, Arroja J D, Banning A, Cuculi F, Kobza R, Fischer T A, Vasankari T, Airaksinen K E J, Napp L C, Budnik M, Dworakowski R, MacCarthy P, Kaiser C, Osswald S, Galiuto L, Chan C, Bridgman P, Beug D, Delmas C, Lairez O, El-Battrawy I, Akin I, Gilyarova E, Shilova A, Gilyarov M, Kozel M, Tousek P, Winchester D E, Galuszka J, Ukena C, Poglajen G, Carrilho-Ferreira P, Hauck C, Paolini C, Bilato C, Prasad A, Rihal C S, Liu K, Schulze P C, Bianco M, Jörg L, Rickli H, Nguyen T H, Kobayashi Y, Böhm M, Maier L S, Pinto F J, Widimský P, Borggrefe M, Felix S B, Opolski G, Braun-Dullaeus R C, Rottbauer W, Hasenfuß G, Pieske B M, Schunkert H, Thiele H, Bauersachs J, Katus H A, Horowitz J, Di Mario C, Münnel T, Crea F, Bax J J, Lüscher T F, Ruschitzka F, Ghadri J R, Templin C. Prediction of short- and long-term mortality in takotsubo syndrome: the InterTAK Prognostic Score. Eur J Heart Fail 2019; 21:1469-1472.
25. Witassek F, Radovanovic D, Erne P, Puhan M, Rickli H, Fehr N. Mortality with antidepressants after acute MI: Antidepressant use after acute myocardial infarction (MI) is associated with an increased mortality 1 year after discharge from Swiss hospitals. Eur Heart J 2019; 40:410.

Nephrologie/Transplantationsmedizin

Wissenschaftliche Artikel

1. Wehmeier C, Karahan G E, Krop J, de Vaal Y, Langerak-Langerak J, Binet I, Schaub S, Roelen D L, Claas F H J, Heidt S, and the Swiss Transplant Cohort Study. Donor-specific B cell memory in alloimmunized kidney transplant recipients - first clinical application of a novel method. Transplantation 2019;.
2. Legendre C, Viebahn R, Crespo M, Dor F, Gustafsson B, Samuel U, Karam V, Binet I, Aberg F, De Geest S, Moes D J A R, Tonshoff B, Oppenheimer F, Asberg A, Halleck F, Loupy A, Suesal C. Beyond Survival in Solid Organ Transplantation: A Summary of Expert Presentations from the Sandoz 6th Standalone Transplantation Meeting, 2018. Transplantation 2019; 103:S1-S13.
3. Vivante A, Chacham O S, Shril S, Schreiber R, Mane S M, Pode-Shakked B, Soliman N A, Koneth I, Schiffer M, Anikster Y, Hildebrandt F. Dominant PAX2 mutations may cause steroid-resistant nephrotic syndrome and FSGS in children. Pediatr Nephrol 2019; 34:1607-1613.
4. Robertz J, Andres M, Mansouri Taleghani B, Koneth I, Binet I, Kremer Hovinga J A. Obinutuzumab in two patients suffering from immune-mediated thrombotic thrombocytopenic purpura intolerant to rituximab. Am J Hematol 2019; 94:E259-E261.

Onkologie/Hämatologie

Wissenschaftliche Artikel

1. Amodio N, Gallo Cantafio M E, Botta C, Agosti V, Federico C, Caracciolo D, Ronchetti D, Rossi M, Driessen C, Neri A, Tagliaferri P, Tassone P. Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. *Cancers (Basel)* 2019; 11:.
2. Amorim A, Bauböck M, Berger J P, Brandner W, Clénet Y, Coudé du Foresto V, de Zeeuw P T, Dexter J, Duvert G, Ebert M, Eckart A, Eisenhauer F, Förster Schreiber N M, Garcia P, Gao F, Gendron E, Genzel R, Gillessen Sommer S, Habibi M, Haubois X, Henning T, Hippler S, Horrobin M, Hubert Z, Jiménez Rosales A, Jocou L, Kervella P, Lacour S, Lapeyrère V, Le Bouquin J B, Léna P, Ott T, Paumard T, Perraut K, Perrin G, Pfuhl O, Rabien S, Rodríguez-Coira G, Rousset G, Scheithauer S, Sternberg A, Straub O, Straubmeier C, Sturm E, Tacconi L J, Vincent F, von Fellenberg S, Waisberg I, Widmann F, Wieprecht E, Wiezorek E, Yazici S, GRAVITY Collaboration . Test of the Einstein Equivalence Principle near the Galactic Center Supermassive Black Hole. *Phys Rev Lett* 2019; 122:101102.
3. Anker M S, Holcomb R, Muscaritoli M, von Haehling S, Haverkamp W, Jatoi A, Morley J E, Strasser F, Landmesser U, Coats A J S, Anker S D. Orphan disease status of cancer cachexia in the USA and in the European Union: a systematic review. *J Cachexia Sarcopenia Muscle* 2019; 10:22-34.
4. Antonarakis E S, Piulats J M, Gross-Goupid M, Goh J, Ojamaa K, Hoimes C J, Vaishampayan U, Berger R, Sezer A, Alanko T, de Wit R, Li C, Omlin A, Procopio G, Fukasawa S, Tabata K I, Park S H, Feyerabend S, Drake C G, Wu H, Qiu P, Kim J, Poehlein C, de Bono J S. Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. *J Clin Oncol* 2019;JCO1901638.
5. Bachner M, Loriot Y, Gross-Goupid M, Zucali P A, Horwich A, Germa-Lluch J R, Kollmannsberger C, Stoiber F, Fléchon A, Oechsle K, Gillessen Sommer S, Oldenburg J, Cohn-Cedermark G, Daugaard G, Morelli F, Sella A, Harland S, Kerst M, Gampe J, Dittrich C, Fizazi K, De Santis M. 2-fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. *Ann Oncol* 2019; 23:59-64.
6. Bauer J, Morley J E, Schols A M W J, Ferrucci L, Cruz-Jentoft A J, Dent E, Baracos V E, Crawford J A, Doehner W, Heymsfield S B, Jatoi A, Kalantar-Zadeh K, Lainscak M, Landi F, Laviano A, Mancuso M, Muscaritoli M, Prado C M, Strasser F, von Haehling S, Coats A J S, Anker S D. Sarcopenia: A Time for Action. An SCWD Position Paper. *J Cachexia Sarcopenia Muscle* 2019; 10:956-961.
7. Besse L, Besse A, Mendez-Lopez M, Vasickova K, Sedlackova M, Vanhara P, Kraus M, Bader J, Ferreira R B, Castellano R K, Law B K, Driessen C. A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis. *Haematologica* 2019; 104:e415-e419.
8. Betschart P, Babst C, Schmid S, Rothermundt C, Abt D, Schwab C, Gillessen Sommer S, Engeler D S, Klingbiel D, Schmid H P, Omlin A. Shared Decision-Making for Patients with Advanced Urological Malignancies: Evaluation of a Joint Urological-Oncological Clinic Model. *Oncol Res Treat* 2019; 42:366-374.
9. Borno H, George D J, Schnipper L E, Cavalli F, Cerny T, Gillessen Sommer S. All Men Are Created Equal: Addressing Disparities in Prostate Cancer Care. *Am Soc Clin Oncol Educ Book* 2019; 39:302-308.
10. Brenig R, Pop O, Triantafyllou E, Geng A, Singanayagam A, Perez Shibayama C, Besse L, Cupovic J, Künzler-Heule P, Boldanova T, Brand S, Semela D, Duong F H, Weston C J, Ludewig B, Heim M H, Wendon J, Antoniades C G, Bernsmeier C. Expression of AXL receptor tyrosine

kinase relates to monocyte dysfunction and severity of cirrhosis. Life Sci Alliance 2019; 3::

11. Bringhen S, Milan A, D'Agostino M, Ferri C, Wäsch R, Gay F, Larocca A, Offidani M, Zweegman S, Terpos E, Goldschmidt H, Cavo M, Ludwig H, Driessen C, Auner H W, Caers J, Gramatzki M, Dimopoulos M A, Boccadoro M, Einsele H, Sonneveld P, Engelhardt M. Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. *J Intern Med* 2019; 286:63-74.
12. Brünnert D, Kraus M, Stühmer T, Kirner S, Heiden R, Goyal P, Driessen C, Bargou R C, Chatterjee M. Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma. *Biochim Biophys Acta Mol Basis Dis* 2019; 1865:1666-1676.
13. Burstein H J, Curigliano G, Loibl S, Dubsky P, Gnant M, Poortmans P, Colleoni M, Denkert C, Piccart-Gebhart M, Regan M, Senn H J, Winer E P, Thürlmann B, Members of the St. Gallen International Consensus Panel on the Primary Therapy of Early Breast Cancer 2019 . Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. *Ann Oncol* 2019; 30:1541-1557.
14. Chow R, Bruera E, Arends J, Walsh D, Strasser F, Isenring E, Del Fabbro E G, Molassiotis A, Krishnan M, Chiu L, Chiu N, Chan S, Tang T Y, Lam H, Lock M, DeAngelis C. Correction to: Enteral and parenteral nutrition in cancer patients, a comparison of complication rates: an updated systematic review and (cumulative) meta-analysis. *Support Care Cancer* 2019;.
15. Chow R, Bruera E, Arends J, Walsh D, Strasser F, Isenring E, Del Fabbro E G, Molassiotis A, Krishnan M, Chiu L, Chiu N, Chan S, Tang T Y, Lam H, Lock M, DeAngelis C. Enteral and parenteral nutrition in cancer patients, a comparison of complication rates: an updated systematic review and (cumulative) meta-analysis. *Support Care Cancer* 2019;.
16. Clarke N W, Ali A, Ingleby F C, Hoyle A, Amos C L, Attard G, Brawley C D, Calvert J, Chowdhury S, Cook A, Cross W, Dearnaley D P, Douis H, Gilbert D, Gillessen S, Jones R J, Langley R E, MacNair A, Malik Z, Mason M D, Matheson D, Millman R, Parker C C, Ritchie A W S, Rush H, Russell J M, Brown J, Beesley S, Birtle A, Capaldi L, Gale J, Gibbs S, Lydon A, Nikapota A, Omlin A, O'Sullivan J M, Parikh O, Protheroe A, Rudman S, Srihari N N, Simms M, Tanguay J S, Tolan S, Wagstaff J, Wallace J, Wylie J, Zarkar A, Sydes M R, Parmar M K B, James N D. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. *Ann Oncol* 2019;.
17. Crombag M R B S, de Vries Schultink A H M, Koolen S L W, Wijngaard S, Joerger M, Schellens J H M, Dorlo T P C, van Erp N P, Mathijssen R H J, Beijnen J H, Huitema A D R. Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study. *Pharm Res* 2019; 36:33.
18. Crombag M R B S, Koolen S L W, Wijngaard S, Joerger M, Dorlo T P C, van Erp N P, Mathijssen R H J, Beijnen J H, Huitema A D R. Does Older Age Lead to Higher Risk for Neutropenia in Patients Treated with Paclitaxel. *Pharm Res* 2019; 36:163.
19. Curigliano G, Burstein H J, P Winer E, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan M M, Piccart-Gebhart M, Senn H J, Thürlmann B, Panel Members of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017 . Corrections to "De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017". *Ann Oncol* 2019; 30:1181.
20. Curigliano G, Burstein H J, P Winer E, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan M M, Piccart-Gebhart M, Senn H J, Thürlmann B, Panel Members of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017 . De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. *Ann Oncol* 2019;.

21. Denkert C, Budczies J, Regan M M, Loibl S, Dell'Orto P, von Minckwitz G, Mastropasqua M G, Solbach C, Thürlmann B, Mehta K, Blohmer J U, Colleoni M, Müller V, Klauschen F, Ataseven B, Engels K, Kammler R, Pfitzner B M, Dietel M, Fasching P A, Viale G. Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial. *Breast Cancer Res Treat* 2019; 176:557-568.
22. Dieckmann K P, Radtke A, Geczi L, Matthies C, Anheuser P, Eckardt U, Sommer J, Zengerling F, Trenti E, Pichler R, Belz H, Zastrow S, Winter A, Melchior S, Hammel J, Kranz J, Bolten M, Krege S, Haben B, Loidl W, Ruf C G, Heinzelbecker J, Heidenreich A, Cremers J F, Oing C, Hermanns T, Fankhauser C D, Gillessen Sommer S, Reichegger H, Cathomas R, Pichler M, Henrich M, Eredics K, Lorch A, Wülfing C, Peine S, Wosniok W, Bokemeyer C, Belge G. Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study. *J Clin Oncol* 2019; 37:1412-1423.
23. Diem S, Fässler M, Bomze D, Ali O H, Berner F, Niederer R, Hillmann D, Mangana J, Levesque M P, Dummer R, Risch L, Recher M, Risch M, Flatz L. Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment. *J Immunother* 2019; 42:89-93.
24. Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, Grünwald V, Gillessen Sommer S, Horwich A, ESMO Guidelines Committee . Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. *Ann Oncol* 2019; 30:706-720.
25. Fässler M, Diem S, Mangana J, Hasan Ali O, Berner F, Bomze D, Ring S, Niederer R, Gil Cruz C, Perez Shibayama C, Krolik M, Siano M, Joerger M, Recher M, Risch L, Güsewell S, Risch M, Speiser D E, Ludewig B, Levesque M P, Dummer R, Flatz L. Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients. *J Immunother Cancer* 2019; 7:50.
26. Fehr M, Cathomas G, Graber A, Markert E, Gaus E, Boggian K. Multi-fungal sepsis and mucormycosis of the central nervous system in a patient treated with ibrutinib, a case report and review of the literature. *Med Mycol Case Rep* 2019; 27:14-16.
27. Ferraro D A, Garcia Schüler H I, Muehlematter U J, Eberli D, Müller J, Müller A, Gablinger R, Kranzbühler H, Omlin A, Kaufmann P A, Hermanns T, Burger I A. Impact of Ga-PSMA-11 PET staging on clinical decision-making in patients with intermediate or high-risk prostate cancer. *Eur J Nucl Med Mol Imaging* 2019;
28. Fischer S, Tandstad T, Cohn-Cedermark G, Thibault C, Vincenzi B, Klingbiel D, Albany C, Necchi A, Terbuch A, Lorch A, Aparicio J, Heidenreich A, Henrich M, Wheater M, Langberg C W, Ståhl O, Fankhauser C D, Hamid A A, Koutsoukos K, Shamash J, White J, Bokemeyer C, Beyer J, Gillessen Sommer S, Global Germ-Cell Cancer Group . Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I Nonseminoma. *J Clin Oncol* 2019;JCO1901876.
29. Früh M, Peters S. EGFR mutation subtype impacts efficacy of immune checkpoint inhibitors in Non-Small Cell Lung Cancer. *Ann Oncol* 2019;:
30. Gillessen Sommer S, Bristow R G. The tip of the iceberg: predicting PARP inhibitor efficacy in prostate cancer. *Lancet Oncol* 2019; 21:17-19.
31. Gillessen Sommer S, Horvath L G. Statins - No more cream for cancer. *Eur J Cancer* 2019; 112:107-108.
32. Gillessen Sommer S, Omlin A, Attard G, de Bono J S, Efstathiou E, Fizazi K, Halabi S, Nelson P S, Sartor O, Smith M R, Soule H R, Akaza H, Beer T M, Beltran H, Chinnaiyan A M, Daugaard G,

- Davis I D, De Santis M, Drake C G, Eeles R A, Fanti S, Gleave M E, Heidenreich A, Hussain M, James N D, Lecouvet F E, Logothetis C J, Mastris K, Nilsson S, Oh W K, Olmos D, Padhani A R, Parker C, Rubin M A, Schalken J A, Scher H I, Sella A, Shore N D, Small E J, Sternberg C N, Suzuki H, Sweeney C J, Tannock I F, Tombal B. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol 2019; 30:e3.
33. Gillessen Sommer S, Tombal B. Management of Prostate Cancer Patients with Clinically Positive Lymph Nodes. Eur Urol Oncol 2019; 2:302-303.
 34. Hamzic S, Kummer D, Froehlich T K, Joerger M, Aebi S, Palles C, Thomlinson I, Meulendijks D, Schellens J H M, García-González X, López-Fernández L A, Amstutz U, Largiadèr C R. Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: an IPD meta-analysis. Pharmacol Res 2019;104594.
 35. Heidenreich A, Gillessen Sommer S, Heinrich D, Keizman D, O'Sullivan J M, Carles J, Wirth M, Miller K, Reeves J, Seger M, Nilsson S, Saad F. Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program. BMC Cancer 2019; 19:12.
 36. Heinhuis K M, Carlino M, Joerger M, Di Nicola M, Meniawy T, Rottey S, Moreno V, Gazzah A, Delord J P, Paz-Ares L, Britschgi C, Schilder R J, O'Byrne K, Curigliano G, Romano E, Patah P, Wang R, Liu Y, Bajaj G, Siu L L. Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial. JAMA Oncol 2019;1-8.
 37. Hench I B, Cathomas R, Costa L, Fischer N, Gillessen Sommer S, Hench J, Hermanns T, Kremer E, Mingrone W, Mestre R P, Püschel H, Rothermundt C, Ruiz C, Tolnay M, Burg P V, Bubendorf L, Vlajnic T, Sakk S G F C C R. Analysis of AR/ARV7 Expression in Isolated Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer (SAKK 08/14 IMPROVE Trial). Cancers (Basel) 2019; 11:.
 38. Herbrand A K, Schmitt A M, Briel M, Diem S, Ewald H, Hoogkamer A, Joerger M, Mc Cord K A, Novak U, Sricharoenchai S, Hemkens L G, Kasenda B. Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project. ESMO Open 2019; 4:e000596.
 39. Hitz F, Kraus M, Pabst T, Hess D, Besse L, Silzle T, Novak U, Seipel K, Rondeau S, Stüdeli S, Vilei S B, Samaras P, Mey U, Driessen C, Swiss Group for Clinical Cancer Research SAKK . Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10). Blood Cancer J 2019; 9:70.
 40. Hoemme A, Barth H, Haschke M, Krähenbühl S, Strasser F, Lehner C, von Kameke A, Wälti T, Thürlmann B, Früh M, Driessen C, Joerger M. Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer. Cancer Chemother Pharmacol 2019; 83:763-774.
 41. Horwich A, Babjuk M, Bellmunt J, Bruins H M, Reijke T M D, Santis M D, Gillessen Sommer S, James N, MacLennan S, Palou J, Powles T, Ribal M J, Shariat S F, Kwast T V D, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black P C, Bochner B H, Bolla M, Boormans J L, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, Bari B D, Blok W D, De Visschere P J L, Decaestecker K, Dimitropoulos K, Dominguez-Escríg J L, Fanti S, Fonteyne V, Frydenberg M, Futterer J J, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel D E, Hartmann A, Hayne D, Henry A M, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa B A, Jones R, Kamat A M, Khoo V, Kiltie A E, Krege S, Ladoire S, Lara P C, Leliveld A, Linares-Espínós E, Løgager V, Lorch A, Loriot Y, Meijer R, Mir M C, Moschini M, Mostafid H, Müller A C, Müller C R, N'Dow J, Necchi A, Neuzillet Y, Oddens J R, Oldenburg J, Osanto S, Oyen W J G, Pacheco-Figueiredo L, Pappot H, Patel M I, Pieters B R, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann

- F, Rosenberg J E, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk R J, Smits A, Stenzl A, Thalmann G N, Tombal B, Turkbey B, Lauridsen S V, Valdagni R, Van Der Heijden A G, Van Poppel H, Vartolomei M D, Veskimäe E, Vilaseca A, Rivera F A V, Wiegel T, Wiklund P, Williams A, Zigeuner R, Witjes J A. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†. *Ann Oncol* 2019; 30:1697-1727.
42. Hoyle A P, Ali A, James N D, Cook A, Parker C C, de Bono J S, Attard G, Chowdhury S, Cross W R, Dearnaley D P, Brawley C D, Gilson C, Ingleby F, Gillessen Sommer S, Aebersold D M, Jones R J, Matheson D, Millman R, Mason M D, Ritchie A W S, Russell M, Douis H, Parmar M K B, Sydes M R, Clarke N W, STAMPEDE Investigators. Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer. *Eur Urol* 2019; 76:719-728.
 43. Hurkmans D P, Basak E A, van Dijk T, Mercieca D, Schreurs M W J, Wijkhuijs A J M, Bins S, Hoop E O D, Debets R, Joerger M, Odink A, van der Veldt A A M, van der Leest C H, Aerts J G J V, Mathijssen R H J, Koolen S L W. A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients. *J Immunother Cancer* 2019; 7:192.
 44. Joerger M, Gueller U, Bastian S, Driessen C, von Moos R. Prolonged tumor response associated with sequential immune checkpoint inhibitor combination treatment and regorafenib in a patient with advanced pretreated hepatocellular carcinoma. *J Gastrointest Oncol* 2019; 10:373-378.
 45. Joerger M, Stathis A, Metaxas Y, Hess D, Mantiero M, Mark M, Volden M, Kaindl T, Engelhardt M, Larger P, Lane H, Hafner P, Levy N, Stuedeli S, Sessa C, von Moos R. A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors. *Invest New Drugs* 2019; .
 46. Joerger M. [Molecularly-targeted anticancer treatments - a short appraisal]. *Ther Umsch* 2019; 76:179-185.
 47. Kensler K H, Regan M M, Heng Y J, Baker G M, Pyle M E, Schnitt S J, Hazra A, Kammler R, Thürlimann B, Colleoni M, Viale G, Brown M, Tamimi R M. Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98. *Breast Cancer Res* 2019; 21:30.
 48. Kollár A, Rothermundt C, Klenke F, Bode B, Baumhoer D, Arndt V, Feller A, NICER Working Group . Incidence, mortality, and survival trends of soft tissue and bone sarcoma in Switzerland between 1996 and 2015. *Cancer Epidemiol* 2019; 63:101596.
 49. Kresoja-Rakic J, Szpechcinski A, Kirschner M B, Ronner M, Minatel B, Martinez V D, Lam W L, Weder W, Stahel R, Früh M, Cerciello F, Felley-Bosco E. miR-625-3p and lncRNA GAS5 in Liquid Biopsies for Predicting the Outcome of Malignant Pleural Mesothelioma Patients Treated with Neo-Adjuvant Chemotherapy and Surgery. *Noncoding RNA* 2019; 5:.
 50. Lam T B L, MacLennan S, Willemse P P M, Mason M D, Plass K, Shepherd R, Baanders R, Bangma C H, Bjartell A, Bossi A, Briers E, Briganti A, Buddingh K T, Catto J W F, Colecchia M, Cox B W, Cumberbatch M G, Davies J, Davis N F, De Santis M, Dell'Olgio P, Deschamps A, Donaldson J F, Egawa S, Fankhauser C D, Fanti S, Fossati N, Gandaglia G, Gillessen Sommer S, Grivas N, Gross T, Grummet J P, Henry A M, Ingels A, Irani J, Lardas M, Liew M, Lin D W, Moris L, Omar M I, Pang K H, Paterson C C, Renard-Penna R, Ribal M J, Roobol M J, Rouprêt M, Rouvière O, Sancho Pardo G, Richenberg J, Schoots I G, Sedelaar J P M, Stricker P, Tilki D, Vahr Lauridsen S, van den Bergh R C N, Van den Broeck T, van der Kwast T H, van der Poel H G, van Leenders G J L H, Varma M, Violette P D, Wallis C J D, Wiegel T, Wilkinson K, Zattoni F, N'Dow J M O, Van Poppel H, Cornford P, Mottet N. EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). *Eur Urol* 2019; 76:790-813.

51. Lin Y H T, Way G P, Barwick B G, Mariano M C, Marcoulis M, Ferguson I D, Driessen C, Boise L H, Greene C S, Wiita A P. Integrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myeloma. *Blood Adv* 2019; 3:3214-3227.
52. Lübbert M, Grishina O, Schmoor C, Schlenk R F, Jost E, Crysandt M, Heuser M, Thol F, Salih H R, Schittenhelm M, Germing U, Kuendgen A, Götze K S, Lindemann H W, Müller-Tidow C, Heil G, Scholl S, Bug G, Schwaenen C, Giagounidis A, Neubauer A, Krauter J, Brugger W, De Wit M, Wäsch R, Becker H, May A M, Duyster J, Döhner K, Ganser A, Hackanson B, Döhner H, DECIDER Study Team . Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial. *J Clin Oncol* 2019;JCO1901053.
53. Mark M, Klingbiel D, Mey U, Winterhalder R, Rothermundt C, Gillessen Sommer S, von Moos R, Pollak M, Manetsch G, Strebler R, Cathomas R. Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb-Pro): Phase 2 Pilot Study. *Clin Genitourin Cancer* 2019;.
54. Mark M, Thürlimann B, Ribi K, Schär C, Dietrich D, Cathomas R, Zürrer-Härdi U, von Briel T, Anchisi S, Bohanes P, Blum V, von Burg P, Mannhart M, Caspar C B, von Moos R. Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16). *J Bone Oncol* 2019; 21:100273.
55. Mazières J, Drilon A, Lusque A, Mhanna L, Cortot A B, Mezquita L, Thai A A, Mascaux C, Couraud S, Veillon R, Van Den Heuvel M, Neal J, Peled N, Früh M, Ng T L, Gounant V, Popat S, Diebold J, Sabari J, Zhu V W, Rothschild S I, Bironzo P, Martinez A, Curioni-Fontecedro A, Rosell R, Lattuca-Truc M, Wiesweg M, Besse B, Solomon B, Barlesi F, Schouten R D, Wakelee H, Camidge D R, Zalcman G, Novello S, Ou S I, Milia J, Gautschi O. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. *Ann Oncol* 2019;.
56. Mendez-Lopez M, Sutter T, Driessen C, Besse L. HIV protease inhibitors for the treatment of multiple myeloma. *Clin Adv Hematol Oncol* 2019; 17:615-623.
57. Molina-Vila M A, Stahel R A, Dafni U, Jordana-Ariza N, Balada-Bel A, Garzón-Ibáñez M, García-Peláez B, Mayo-de-Las-Casas C, Felip E, Fontecedro A C, Gautschi O, Peters S, Massutí B, Palmero R, Aix S P, Carcereny E, Früh M, Pless M, Popat S, Cuffe S, Bidoli P, Kammler R, Roschitzki-Voser H, Tsourtzi Z, Karachaliou N, Rosell R, results from the European Thoracic Oncology Platform (ETOP) BELIEF trial . Evolution and clinical impact of EGFR mutations in circulating free DNA in the BELIEF trial. *J Thorac Oncol* 2019;.
58. Mukherji D, Youssef B, Dagher C, El-Hajj A, Nasr R, Geara F, Rabah D, Al Dousari S, Said R, Ashou R, Wazzan W, Jabbour M, Farha G, Al Hamdani N, Al Hallaq Y, Ghazal H, Dbouk H, Bachir B, El Khoury C, Sakr G, Hussain H K, Sayyid K, Ibrahim K, Haidar M, Zouain N, Bitar N, Alameh W, Abbas F, Faddoul S, Nemer E, Assaf G, Farhat F, Bulbul M, Temraz S, Shamseddine A, Gillessen Sommer S, Omlin A, Khauli R. Management of patients with high-risk and advanced prostate cancer in the Middle East: resource-stratified consensus recommendations. *World J Urol* 2019;.
59. O'Brien O, Wright M C, O'Brien C, Geoghegan O, Leonard N, Nicholson S, Cuffe S, Fabre A, Jochum W, Joerger M, Gray S G, Finn S P. Cost-Efficient and Easy to Perform PCR-Based Assay to Identify Met Exon 14 Skipping in Formalin-Fixed Paraffin-Embedded (FFPE) Non-Small Cell Lung Cancer (NSCLC) Samples. *Diagnostics (Basel)* 2019; 9:..
60. Omlin A, Gillessen Sommer S. The Advanced Prostate Cancer Consensus on a regional level - what can we learn. *BJU Int* 2019; 123:3-4.
61. Papachristofilou A, Hipp M M, Klinkhardt U, Früh M, Sebastian M, Weiss C, Pless M, Cathomas R, Hilbe W, Pall G, Wehler T, Alt J, Bischoff H, Geißler M, Griesinger F, Kallen K J, Fotin-Mleczek

- M, Schröder A, Scheel B, Muth A, Seibel T, Stosnach C, Doener F, Hong H S, Koch S D, Gnad-Vogt U, Zippelius A. Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer. *J Immunother Cancer* 2019; 7:38.
62. Perez-Lopez R, Tunariu N, Padhani A R, Oyen W J G, Fanti S, Vargas H A, Omlin A, Morris M J, De Bono J, Koh D M. Imaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the Art. *Radiology* 2019; 292:273-286.
 63. Plummer C, Driessen C, Szabo Z, Mateos M V. Management of cardiovascular risk in patients with multiple myeloma. *Blood Cancer J* 2019; 9:26.
 64. Putora P M, Glatzer M, Belderbos J, Besse B, Blackhall F, Califano R, Cappuzzo F, de Marinis F, Dziadziuszko R, Felip E, Faivre-Finn C, Früh M, Garrido P, Le Pechoux C, McDonald F, Nestle U, Novello S, O'Brien M, Paz Ares L, Peeters S, Pöttgen C, Ramella S, Reck M, Slotman B, Troost E G C, Van Houtte P, Westeel V, Widder J, Mornex F, De Ruysscher D. Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. *Radiother Oncol* 2019; 133:163-166.
 65. Putora P M, Glatzer M, De Ruysscher D, Faivre-Finn C, Belderbos J, Besse B, Blackhall F, Califano R, Cappuzzo F, de Marinis F, Dziadziuszko R, Felip E, Früh M, Garrido P, Le Pechoux C, McDonald F, Nestle U, Novello S, Brien M O, Paz Ares L, Peeters S, Pöttgen C, Ramella S, Reck M, Troost E G C, Van Houtte P, Westeel V, Widder J, Mornex F, Slotman B J. Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. *Radiother Oncol* 2019; 135:74-77.
 66. Putora P M, Glatzer M, De Ruysscher D, Faivre-Finn C, Belderbos J, Besse B, Blackhall F, Califano R, Cappuzzo F, de Marinis F, Dziadziuszko R, Felip E, Früh M, Garrido P, Le Pechoux C, McDonald F, Nestle U, Novello S, O' Brien M, Paz Ares L, Peeters S, Pöttgen C, Ramella S, Reck M, Troost E G C, Van Houtte P, Westeel V, Widder J, Mornex F, Slotman B J. Erratum to "Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts" [Radiother. Oncol. 135 (2019) 74-77]. *Radiother Oncol* 2019; 141:332.
 67. Rebello R J, Oing C, Gillessen Sommer S, Bristow R G. and Prognosis in mCRPC Survival: Biology or Coincidence. *Clin Cancer Res* 2019; 25:1699-1701.
 68. Renz M, Büche D, Reichmuth O, Schuett Mao M, Renz U, Siebenrock R, Strasser F. Forgiveness and Reconciliation Processes in Dying Patients With Cancer. *Am J Hosp Palliat Care* 2019;1049909119867675.
 69. Rescigno P, Dolling D, Conteduca V, Rediti M, Bianchini D, Lolli C, Ong M, Li H, Omlin A, Schmid S, Caffo O, Zivi A, Pezaro C J, Morley C, Olmos D, Romero-Laorden N, Castro E, Saez M I, Mehra N, Smeenk S, Sideris S, Gil T, Banks P, Sandhu S K, Sternberg C N, De Giorgi U, de Bono J S. Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis. *Eur Urol Oncol* 2019;;
 70. Saad F, Gillessen Sommer S, Heinrich D, Keizman D, O'Sullivan J M, Nilsson S, Miller K, Wirth M, Reeves J, Seger M, Carles J, Heidenreich A. Disease Characteristics and Completion of Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in an International Early Access Program. *Clin Genitourin Cancer* 2019; 17:348-355.e5.
 71. Samaras P, Bargetzi M, Betticher D C, Driessen C, Duchosal M A, Heim D, Ketterer N, Lerch E, Matthes T, Mey U, Pabst T, Schmidt A, Taverna C, Zander T, Renner C. Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland. *Swiss Med Wkly* 2019; 149:w20031.

72. Schett A, Rothschild S I, Curioni-Fontecedro A, Krähenbühl S, Früh M, Schmid S, Driessen C, Joerger M. Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors: Antibiotics immune checkpoint inhibitors in advanced NSCLC. *Cancer Chemother Pharmacol* 2019;.
73. Schiavone F, Bathia R, Letchemanan K, Masters L, Amos C, Bara A, Brown L, Gilson C, Pugh C, Atako N, Hudson F, Parmar M, Langley R, Kaplan R S, Parker C, Attard G, Clarke N W, Gillessen Sommer S, James N D, Maughan T, Sydes M R, past and present members of the STAMPEDE and FOCUS4 Trial Management Group . This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols. *Trials* 2019; 20:264.
74. Schittenhelm M, Walter B, Tsintari V, Federmann B, Bajrami Saipi M, Akmut F, Illing B, Mau-Holzmann U, Fend F, Lopez C D, Kampa-Schittenhelm K M. Alternative splicing of the tumor suppressor ASPP2 results in a stress-inducible, oncogenic isoform prevalent in acute leukemia. *EBioMedicine* 2019; 42:340-351.
75. Schmid S, Aepli S, Früh M. Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort. *lungcancer* 2019;.
76. Schmid S, Klingbiel D, Aebi S, Goldhirsch A, Mamot C, Munzone E, Nolè F, Oehlschlegel C, Pagani O, Pestalozzi B, Rochlitz C, Thürlimann B, von Moos R, Weder P, Zaman K, Ruhstaller T. Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data. *BMC Cancer* 2019; 19:902.
77. Schmid S, Klingbiel D, Aepli S, Britschgi C, Gautschi O, Pless M, Rothschild S, Wannesson L, Janthur W, Foerbs D, Demmer I, Jochum W, Früh M. Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study. *Lung Cancer* 2019; 130:149-155.
78. Schmid S, Omzin A. Progress in therapy across the spectrum of advanced prostate cancer. *Nat Rev Urol* 2019;.
79. Schneeweiss A, Hess D, Joerger M, Varga A, Moulder S, Tsimberidou A M, Ma C, Hurvitz S A, Rentzsch C, Rudolph M, Thiele S, Boix O, Wilkinson G, Lagkadinou E, Ocker M. Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy. *Cancers (Basel)* 2019; 11:.
80. Schoch O, Baty F, Bösch M, Benz G, Niedermann J, Brutsche M. Telemedicine for Continuous Positive Airway Pressure in Sleep Apnea: A Randomized, Controlled Study. *Ann Am Thorac Soc* 2019;.
81. Schuler M, Cho B C, Sayehli C M, Navarro A, Soo R A, Richly H, Cassier P A, Tai D, Penel N, Nogova L, Park S H, Schostak M, Gajate P, Cathomas R, Rajagopalan P, Grevel J, Bender S, Boix O, Nogai H, Ocker M, Ellinghaus P, Joerger M. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study. *Lancet Oncol* 2019;.
82. Silzle T, Blum S, Schuler E, Kaivers J, Rudelius M, Hildebrandt B, Gattermann N, Haas R, Germing U. Lymphopenia at diagnosis is highly prevalent in myelodysplastic syndromes and has an independent negative prognostic value in IPSS-R-low-risk patients. *Blood Cancer J* 2019; 9:63.
83. Trefny M P, Rothschild S I, Uhlenbrock F, Rieder D, Kasenda B, Stanczak M A, Berner F, Kashyap A S, Kaiser M, Herzig P, Poechtrager S, Thommen D S, Geier F, Savic S, Jermann P, Alborelli I, Schaub S, Stenner F, Früh M, Trajanoski Z, Flatz L, Mertz K D, Zippelius A, Läubli H. A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer. *Clin Cancer Res* 2019; 25:3026-3034.

84. Überall I, Gachechiladze M, Joerger M, Anděl J, Smičková P, Kolek V, Grygárová I, Škarda J. Tumor autophagy is associated with survival outcomes in patients with resected non-small cell lung cancer. *Lung Cancer* 2019; 129:85-91.
85. Vagnildhaug O M, Brunelli C, Hjermstad M J, Strasser F, Baracos V, Wilcock A, Nabal M, Kaasa S, Laird B, Solheim T S. A prospective study examining cachexia predictors in patients with incurable cancer. *BMC Palliat Care* 2019; 18:46.
86. van den Bent M, Azaro A, De Vos F, Sepulveda J, Yung W K A, Wen P Y, Lassman A B, Joerger M, Tabatabai G, Rodon J, Tiedt R, Zhao S, Kirsilae T, Cheng Y, Vicente S, Balbin O A, Zhang H, Wick W. A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma. *J Neurooncol* 2019;.
87. Van den Broeck T, van den Bergh R C N, Briers E, Cornford P, Cumberbatch M, Tilki D, De Santis M, Fanti S, Fossati N, Gillessen Sommer S, Grummet J P, Henry A M, Lardas M, Liew M, Mason M, Moris L, Schoots I G, van der Kwast T, van der Poel H, Wiegel T, Willemse P P M, Rouvière O, Lam T B, Mottet N. Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations. *Eur Urol Focus* 2019;.
88. VanderWeele D J, Antonarakis E S, Carducci M A, Dreicer R, Fizazi K, Gillessen Sommer S, Higano C S, Morgans A K, Petrylak D P, Sweeney C J, Hussain M. Metastatic Hormone-Sensitive Prostate Cancer: Clinical Decision Making in a Rapidly Evolving Landscape of Life-Prolonging Therapy. *J Clin Oncol* 2019; 37:2961-2967.
89. Varga Z, Li Q, Jochum W, Perriard U, Rau T, Tille J C, Hawle H, Klingbiel D, Thürlimann B, Ruhstaller T. Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort. *Sci Rep* 2019; 9:13534.
90. Vrabel D, Sedlarikova L, Besse L, Rihova L, Bezdekova R, Almasi M, Kubaczkova V, Brožová L, Jarkovsky J, Plonkova H, Jelinek T, Sandecka V, Stork M, Pour L, Sevcikova S, Hájek R. Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients. *Eur J Haematol* 2019;.
91. Williams E H, Connell C M, Weaver J M J, Beh I, Potts H, Whitley C T, Bird N, Al-Sayed T, Monaghan P J, Fehr M, Cathomas R, Bertelli G, Quinton A, Lewis P, Shamash J, Wilson P, Dooley M, Poole S, Mark P B, Bookman M A, Earl H, Jodrell D, Tavaré S, Lynch A G, Janowitz T. Multicenter Validation of the CamGFR Model for Estimated Glomerular Filtration Rate. *JNCI Cancer Spectr* 2019; 3:pkz068.
92. Wirth M, Fossati N, Albers P, Bangma C, Brausi M, Compérat E, Faithfull S, Gillessen Sommer S, Jereczek-Fossa B A, Mastris K, Mottet N, Müller S C, Pieters B, Ribal M J, Sangar V, Schoots I G, Smelov V, Travado L, Valdagni R, Wesselmann S, Wiegel T, Van Poppel H. The European Prostate Cancer Centres of Excellence: A Novel Proposal from the European Association of Urology Prostate Cancer Centre Consensus Meeting. *Eur Urol* 2019; 76:179-186.
93. Witjes J A, Babjuk M, Bellmunt J, Bruins H M, De Reijke T M, De Santis M, Gillessen Sommer S, James N, MacLennan S, Palou J, Powles T, Ribal M J, Shariat S F, Der Kwast T V, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black P C, Bochner B H, Bolla M, Boormans J L, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, De Bari B, De Blok W, J L De Visschere P, Decaestecker K, Dimitropoulos K, Dominguez-Escrí J L, Fanti S, Fonteyne V, Frydenberg M, Futterer J J, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel D E, Hartmann A, Hayne D, Henry A M, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa B A, Jones R, Kamat A M, Khoo V, Kiltie A E, Krege S, Ladoire S, Lara P C, Leliveld A, Linares-Espínós E, Løgager V, Lorch A, Loriot Y, Meijer R, Mir M C, Moschini M, Mostafid H, Müller A C, Müller C R, N'Dow J, Necchi A, Neuzillet Y, Oddens J R, Oldenburg J, Osanto S, J G Oyen W, Pacheco-Figueiredo L, Pappot H, Patel M I, Pieters B R, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann

F, Rosenberg J E, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk R J, Smits A, Stenzl A, Thalmann G N, Tombal B, Turkbey B, Lauridsen S V, Valdagni R, Der Heijden A G V, Van Poppel H, Vartolomei M D, Veskimäe E, Vilaseca A, Rivera F A V, Wiegel T, Wiklund P, Williams A, Zigeuner R, Horwich A. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort: Under the Auspices of the EAU-ESMO Guidelines Committees. Eur Urol 2019; 77:223-250.

94. Xin B T, Huber E M, de Bruin G, Heinemeyer W, Maurits E, Espinal C, Du Y, Janssens M, Weyburne E S, Kisselev A F, Florea B I, Driessen C, van der Marel G A, Groll M, Overkleef H S. Structure-Based Design of Inhibitors Selective for Human Proteasome β 2c or β 2i Subunits. J Med Chem 2019; 62:1626-1642.
95. Zucca E, Rondeau S, Vanazzi A, Østenstad B, Mey U J M, Rauch D, Wahlin B E, Hitz F, Hernberg M, Johansson A S, de Nully Brown P, Hagberg H, Ferreri A J M, Lohri A, Novak U, Zander T, Bersvendsen H, Bargetzi M, Mingrone W, Krasniqi F, Dirnhofer S, Hayoz S, Hawle H, Vilei S B, Ghielmini M, Kimby E, Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group . Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy. Blood 2019; 134:353-362.

Pneumologie/Schlafmedizin

Wissenschaftliche Artikel

1. Albrich W, Rassouli F, Waldeck F, Berger C, Baty F. Influence of Older Age and Other Risk Factors on Pneumonia Hospitalization in Switzerland in the Pneumococcal Vaccine Era. Front Med (Lausanne) 2019; 6:286.
2. Bösch M, Baty F, Rumpold H, Sopper S, Wolf D, Brutsche M. Fibroblasts in cancer: Defining target structures for therapeutic intervention. Biochim Biophys Acta Rev Cancer 2019; 1872:111-121.
3. Fontana P, Martins N R A, Camenzind M, Rossi R M, Baty F, Bösch M, Schoch O, Brutsche M, Annaheim S. Clinical Applicability of a Textile 1-Lead ECG Device for Overnight Monitoring. Sensors (Basel) 2019; 19:..
4. Hatina J, Bösch M, Sopper S, Kripnerova M, Wolf D, Reimer D, Marth C, Zeimet A G. Ovarian Cancer Stem Cell Heterogeneity. Adv Exp Med Biol 2019; 1139:201-221.
5. Papakonstantinou E, Bonovolias I, Roth M, Tamm M, Schumann D, Baty F, Louis R, Milenkovic B, Boersma W, Stieljes B, Kostikas K, Blasi F, Aerts J G, Rohde G G U, Lacoma A, Torres A, Welte T, Stolz D. Serum levels of hyaluronic acid are associated with COPD severity and predict survival. Eur Respir J 2019; 53:..
6. Schoch O, Baty F, Bösch M, Benz G, Niedermann J, Brutsche M. Telemedicine for Continuous Positive Airway Pressure in Sleep Apnea: A Randomized, Controlled Study. Ann Am Thorac Soc 2019;..
7. Sievi N A, Kohler M, Thurnheer R, Leuppi J D, Irani S, Frey M, Brutsche M, Brack T, Clarenbach C F. No impact of exacerbation frequency and severity on the physical activity decline in COPD: a long-term observation. Int J Chron Obstruct Pulmon Dis 2019; 14:431-437.
8. Tinschert P, Rassouli F, Barata F, Steurer-Stey C, Fleisch E, Puhan M A, Brutsche M, Kowatsch T. Prevalence of nocturnal cough in asthma and its potential as a marker for asthma control (MAC) in combination with sleep quality: protocol of a smartphone-based, multicentre, longitudinal observational study with two stages. BMJ Open 2019; 9:e026323.
9. Wolf D, Fiegl H, Zeimet A G, Wieser V, Marth C, Sprung S, Sopper S, Hartmann G, Reimer D, Bösch M. High RIG-I expression in ovarian cancer associates with an immune-escape signature

and poor clinical outcome. Int J Cancer 2019;.

Rheumatologie

Wissenschaftliche Artikel

1. Bühler S, Jaeger V K, Adler S, Bannert B, Brümmerhoff C, Ciurea A, Distler O, Franz J, Gabay C, Hagenbuch N, Herzog C, Hasler P, Kling K, Kyburz D, Müller R, Nissen M J, Siegrist C A, Villiger P M, Walker U A, Hatz C. Safety and immunogenicity of tetanus/diphtheria vaccination in patients with rheumatic diseases-a prospective multi-centre cohort study. *Rheumatology (Oxford)* 2019;.
2. Burmester G R, Strand V, Rubbert-Roth A, Amital H, Raskina T, Gómez-Centeno A, Pena-Rossi C, Gervitz L, Thangavelu K, St John G, Boklage S, Genovese M C. Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension. *RMD Open* 2019; 5:e001017.
3. Deutsche S, Reschling N, Villiger R, Villiger P M, Valletian F, Scher D, Mueller R B. 51-year-old man with acute coronary syndrome and bipulmonary infiltrates. *Swiss Medical Weekly* 2019; 2019;149:w20022:.
4. Dörner T, Schulze-Koops H, Burmester G R, Iking-Konert C, Schmalzing M, Engel A, Kästner P, Kellner H, Kurthen R, Krüger K, Rubbert-Roth A, Schwenke H, Peters M A, Tony H P. Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI). *Clin Exp Rheumatol* 2019; 37:937-945.
5. Drinda S, Grundler F, Neumann T, Lehmann T, Steckhan N, Michalsen A, de Toledo F W. Effect of Therapeutic Fasting on Fatty Liver Index – a prospective observational study. *Nutrients* 2019; 11:.
6. Galli E, Rossi J, Neumann T, Andressoo J O, Drinda S, Lindholm P. Mesencephalic Astrocyte-Derived Neurotrophic Factor Is Upregulated with Therapeutic Fasting in Humans and Diet Fat Withdrawal in Obese Mice. *Sci Rep* 2019; 9:14318.
7. Krause A, Rubbert-Roth A. [Pulmonary involvement in rheumatoid arthritis]. *Z Rheumatol* 2019; 78:228-235.
8. Lyons P A, Peters J E, Alberici F, Liley J, Coulson R M R, Astle W, Baldini C, Bonatti F, Cid M C, Elding H, Emmi G, Epplen J, Guillemin L, Jayne D R W, Jiang T, Gunnarsson I, Lamprecht P, Leslie S, Little M A, Martorana D, Moosig F, Neumann T, Ohlsson S, Quickert S, Ramirez G A, Rewerska B, Schett G, Sinico R A, Szczeklik W, Tesar V, Vukcevic D, European Vasculitis Genetics Consortium , Terrier B, Watts R A, Vaglio A, Holle J U, Wallace C, Smith K G C. Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. *Nat Commun* 2019; 10:5120.
9. Marvisi C, Sinico R A, Salvarani C, Jayne D, Prisco D, Terrier B, Emmi G, Vaglio A, European EGPA Study Group . New perspectives in eosinophilic granulomatosis with polyangiitis (EGPA): report of the first meeting of the European EGPA Study Group. *Intern Emerg Med* 2019; 14:1193-1197.
10. Mueller R B, Hasler C, Popp F, Mattow F, Durmisi M, Souza A, Hasler P, Rubbert-Roth A, Schulze-Koops H, von Kempis J. Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau Cohorts. *J Clin Med* 2019; 8:.
11. Mueller R B, Spaeth M, von Restorff C, Ackermann C, Schulze-Koops H, von Kempis J. Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate

Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol. J Clin Med 2019; 8:.

12. Pirker I F J, Rein P, von Kempis J. Important differential diagnosis in acute tenosynovitis. BMJ Case Rep 2019; 12:.
13. Poddubnyy D, Amital H, Rubbert-Roth A. Should we combine biologics with methotrexate in axial spondyloarthritis. Autoimmun Rev 2019; 18:102402.
14. Rubbert-Roth A, Szabó M Z, Kedves M, Nagy G, Atzeni F, Sarzi-Puttini P. Failure of anti-TNF treatment in patients with rheumatoid arthritis: The pros and cons of the early use of alternative biological agents. Autoimmun Rev 2019; 18:102398.
15. von Kempis J, Duetsch S, Reuschling N, Villiger R, Villiger P M, Valletian F, Schaer D J, Mueller R B. Clinical outcomes in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: a retrospective analysis of results from the OBSErve study in Switzerland. Swiss Med Wkly 2019; 149:w20022.
16. von Kempis J, von Restorff C, Spaeth M, Ackermann C, Schulze-Koops H. Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol. Journal of Clinical Medicine 2019; 8:302.

Departement II

Anästhesiologie/Intensivmedizin

Wissenschaftliche Artikel

1. Bollen Pinto B, Filipovic M, Ackland G. Intra-operative heart rate and postoperative outcomes - rowing against the tide. Eur J Anaesthesiol 2019; 36:90-92.
2. Endermann S, Korte W, Filipovic M. Airway Obstruction Caused by Hemorrhage: Managing a Life-Threatening Complication in Patients With Acquired Hemophilia A: A Case Report. A A Pract 2019;.
3. Ott A. Intradural non-calcified thoracic disc herniation causing spontaneus intracranial hypotension: a case report. BMC Surgery (2019) 2019; 19:.
4. Pietsch U, Strapazzon G, Ambühl D, Lischke V, Rauch S, Knapp J. Challenges of helicopter mountain rescue missions by human external cargo: need for physicians onsite and comprehensive training. Scand J Trauma Resusc Emerg Med 2019; 27:17.
5. Rotsel E, Pietsch U. [Severe SGLT-2 inhibitor-induced euglycemic ketoacidosis-a rare but serious complication]. Anaesthetist 2019;.
6. Schnider T, Minto C F, Egan T D, Filipovic M. Correlation between bispectral index and age-adjusted minimal alveolar concentration. Br J Anaesth 2019; 124:e8.
7. Schnider T, Minto C F, Egan T D, Filipovic M. Patient Factors Affecting Bispectral Index During Total Intravenous Anesthesia With Target-Controlled Infusion. Anesth Analg 2019;.
8. von Hösslin T, Imboden P, Kaufmann C, Schnider T, Filipovic M. Outcome after out-of-hospital ventricular fibrillation or pulseless ventricular tachycardia: comparison of before and after the implementation of the 2010 Guidelines in a single centre. Swiss Med Wkly 2019; 149:w20101.

Klinik für Allgemein-, Viszeral-, Endokrin- und Transplantationschirurgie

Wissenschaftliche Artikel

1. Antony P, Harnoss J C, Warschkow R, Schmied B, Schneider M, Tarantino I, Ulrich A. Urgent surgery in colon cancer has no impact on survival. J Surg Oncol 2019; 119:1170-1178.
2. Barski D, Gerullis H, Ecke T, Boros M, Brune J, Beutner U, Tsaur I, Ramon A, Otto T. Application of Dried Human Amnion Graft to Improve Post-Prostatectomy Incontinence and Potency: A Randomized Exploration Study Protocol. Adv Ther 2019; 37:592-602.
3. Erdem S, Troxler E, Warschkow R, Tsai C, Yerokun B, Schmied B, Stettler C, Blazer D G, Hartwig M, Worni M, Gloor B. Is There a Role for Surgery in Patients with Neuroendocrine Tumors of the Esophagus? A Contemporary View from the NCDB. Ann Surg Oncol 2019;.
4. Erdem S, Warschkow R, Worni M. Reply to the Editor: "Is There a Role of Surgery in Treating Localized Esophageal Neuroendocrine Tumor?". Ann Surg Oncol 2019;.
5. Konschake M, Zwierzina M, Moriggl B, Függer R, Mayer F, Brunner W, Schmid T, Chen D C, Fortelny R. The inguinal region revisited: the surgical point of view : An anatomical-surgical mapping and sonographic approach regarding postoperative chronic groin pain following open hernia repair. Hernia 2019;.
6. Kovacevic D, Ukegjini K, Lionetto S. Divertikulitis einmal anders : Korrekte Diagnose erst retrospektiv. Swiss Med Forum 2019; 19:335-337.

7. Steffen T, Ebinger S M, Tarantino I, Widmann B. Prognostic Impact of Lymph Node Excision in T1 and T2 Gallbladder Cancer: a Population-Based and Propensity Score-Matched SEER Analysis. *J Gastrointest Surg* 2019;.
8. Steffen T, Putora P M, Hübner M, Gloor B, Lehmann K, Kettelhack C, Adamina M, Peterli R, Schmidt J, Ris F, Glatzer M. Diagnostic Nodes of Patient Selection for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Among Colorectal Cancer Patients: A Swiss National Multicenter Survey. *Clin Colorectal Cancer* 2019; 18:e335-e342.
9. Tsai C, Mueller A, Maubach J, Warschkow R, Nussbaum D P, Schmied B, Blazer D, Gloor B, Worni M. No Difference in Survival between Neo-Adjuvant Chemotherapy and Neo-Adjuvant Chemoradiation Therapy in Gastric Cardia Cancer Patients: A Contemporary View from the National Cancer Database. *Dig Surg* 2019;1-9.
10. Ulug P, Powell J T, Warschkow R, von Allmen R. Editor's Choice - Sex Specific Differences in the Management of Descending Thoracic Aortic Aneurysms: Systematic Review with Meta-Analysis. *Eur J Vasc Endovasc Surg* 2019; 58:503-511.
11. Widmann B, Galata C, Warschkow R, Beutner U, Ögredici , Hetzer F H, Schmied B, Post S, Marti L. Success and Complication Rates After Sacral Neuromodulation for Fecal Incontinence and Constipation: A Single-center Follow-up Study. *J Neurogastroenterol Motil* 2019; 25:159-170.
12. Wurster E F, Pianka F, Warschkow R, Antony P, Brenner T, Weigand M A, Schmied B, Büchler M W, Tarantino I, Ulrich A. Peridural analgesia does not impact survival in patients after colon cancer resection: a retrospective propensity score-adjusted analysis. *Int J Colorectal Dis* 2019; 34:1283-1293.
13. Zulewski H, Giovanella L, Bilz S, Christ E, Haldemann A, Steinert H, Weidner S, Oertli D, Triponez F, Clerici T, Minder A, Dettmer M, Komminoth P. Multidisciplinary approach for risk-oriented treatment of low-risk papillary thyroid cancer in Switzerland. *Swiss Med Wkly* 2019; 149:w14700.

Klinik für Gefässchirurgie

Wissenschaftliche Artikel

1. Conte M S, Bradbury A W, Kohl P, White J V, Dick F, Fitridge R, Mills J L, Ricco J B, Suresh K R, Murad M H, Aboyans V, Aksoy M, Alexandrescu V A, Armstrong D, Azuma N, Belch J, Bergoeing M, Bjorck M, Chakfé N, Cheng S, Dawson J, Debus E S, Dueck A, Duval S, Eckstein H H, Ferraresi R, Gambhir R, Garguilo M, Geraghty P, Goode S, Gray B, Guo W, Gupta P C, Hinchliffe R, Jetty P, Komori K, Lavery L, Liang W, Lookstein R, Menard M, Misra S, Miyata T, Moneta G, Munoa Prado J A, Munoz A, Paolini J E, Patel M, Pomposelli F, Powell R, Robless P, Rogers L, Schanzer A, Schneider P, Taylor S, Vega de Ceniga M, Veller M, Vermassen F, Wang J, Wang S, GVG Writing Group for the Joint Guidelines of the Society for Vascular Surgery (SVS) , European Society for Vascular Surgery (ESVS), and World Federation of Vascular Societies (WFVS) . Corrigendum to 'Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia' [European Journal of Vascular & Endovascular Surgery 58/1S (2019) 1-109]. *Eur J Vasc Endovasc Surg* 2019;.
2. Kohl P, Dick F, Sillesen H. EJVES, the Leading Journal in Vascular Surgery, is One of the Numerous Scientific Pillars of the ESVS. *Eur J Vasc Endovasc Surg* 2019; 58:311-314.
3. Sillesen H, Debus S, Dick F, Eiberg J, Halliday A, Haulon S, Jongkind V, Verhagen H, Vikatmaa P, Kohl P. Long Term Evaluation Should Be an Integral Part of the Clinical Implementation of New Vascular Treatments - an ESVS Executive Committee Position Statement. *Eur J Vasc Endovasc Surg* 2019; 58:315-317.

4. Ulug P, Powell J T, Warschkow R, von Allmen R. Editor's Choice - Sex Specific Differences in the Management of Descending Thoracic Aortic Aneurysms: Systematic Review with Meta-Analysis. *Eur J Vasc Endovasc Surg* 2019; 58:503-511.
5. von Allmen R, Tinner C, Schmidli J, Tevaeearai H T, Dick F. Randomized controlled comparison of cross-sectional survey approaches to optimize follow-up completeness in clinical studies. *PLoS ONE* 2019; 14:e0213822.
6. Wanhainen A, Verzini F, Van Herzele I, Allaure E, Bown M, Cohnert T, Dick F, van Herwaarden J, Karkos C, Koelemay M, Kölbel T, Loftus I, Mani K, Melissano G, Powell J, Szeberin Z, Esvs Guidelines Committee , de Borst G J, Chakfé N, Debus S, Hinchliffe R, Kakkos S, Koncar I, Kolh P, Lindholt J S, Vega de Ceniga M, Vermassen F, Document Reviewers , Bjorck M, Cheng S, Dalman R, Davidovic L, Donas K, Earnshaw J, Eckstein H H, Golledge J, Haulon S, Mastracci T, Naylor R, Ricco J B, Verhagen H. Corrigendum to 'European Society for Vascular Surgery (ESVS) 2019 Clinical Practice Guidelines on the Management of Abdominal Aorto-iliac Artery Aneurysms' [European Journal of Vascular & Endovascular Surgery 57/1 (2019) 8-93]. *Eur J Vasc Endovasc Surg* 2019; 59:494.
7. White J V, Conte M, Bradbury A, Kolh P, Dick F, Fitridge R, Mills J, Ricco J B, Suresh K. Building a global alliance in vascular surgery. *J Vasc Surg* 2019; 70:663-664.
8. White J, Conte M, Bradbury A, Kolh P, Dick F, Fitridge R, Mills J, Ricco J B, Suresh K. Building a Global Alliance in Vascular Surgery. *Eur J Vasc Endovasc Surg* 2019; 58:318-319.

Frauenklinik

Wissenschaftliche Artikel

1. Anthis A H C, Tsolaki E, Didierlaurent L, Staubli S, Zboray R, Neels A, Dietrich D, Manser P, Desbiolles L M, Leschka S, Wildermuth S, Lehner S, Chavatte-Palmer P, Jochum W, Wick P, Dommann A, Bürki-Turnherr T, Fischer T, Hornung R, Bertazzo S, Herrmann I K. Nano-analytical characterization of endogenous minerals in healthy placental tissue: mineral distribution, composition and ultrastructure. *Analyst* 2019; 144:6850-6857.
2. Biener, geb. Schulze Pröbsting A, Fischer T. Medikamente in der Schwangerschaft. der informierte @rzt 2019; 9:15-17.
3. Fischer T, Kinkel J. Fetale Hydronephrose. info@gynäkologie 2019; 9:28-30.
4. Fischer T, Kinkel J. Kongenitale Ichthyose: Hyperechogenes Fruchtwasser als mögliches Zeichen einer Pathologie. info@gynäkologie 2019; 9:24-25.
5. Häberlin F. Kindeswohl und Patientenwohl in der Fortpflanzungsmedizin. *Leading Opinions (Gynäkologie & Geburtshilfe)* 2019; 12:30-34.
6. Hornung R, Baldinger J. Pilz, Juckreiz und Dyspareunie. der informierte @rzt 2019; 9:7-10.
7. Kahr M K, Winder, geb. Lang F, Vonzen L, Meuli M, Mazzone L, Moehrlen U, Krähenmann F, Hüslar M, Zimmermann R, Ochsenbein-Köble N. Risk Factors for Preterm Birth following Open Fetal Myelomeningocele Repair: Results from a Prospective Cohort. *Fetal Diagn Ther* 2019;1-9.
8. Kühn-Lichtenberg A, Hornung R. Schmerzen in der Brust. der informierte @rzt 2019; 9:11-13.
9. Kühn-Lichtenberg A, Hornung R. Schmerzen in der Brust. info@gynäkologie 2019; 9:18-20.
10. Lorenz P, Waibel P, Malzacher A. Aspiration pneumonia in a newborn following water birth. *Swiss Society of Neonatology* 2019; Case of the Month 03:1-10.
11. Winder, geb. Lang F, Hornung R. Frühabortion: Alternativen zur chirurgischen Therapie. info@gynäkologie 2019; 9:10-11.

Klinik für Orthopädische Chirurgie

Buch

1. Beck M; Zdravkovic V; Christen B: SIRIS Report 2019 : Annual Report of the Swiss National Joint Registry, Hip and Knee, 2012 – 2018. Bern : ANQ, 2019

Buchkapitel

1. Puskas G; Jost B: Muskeltransferoperationen. In: Die Rotatorenmanschette: Grundlagen, Diagnostik, und Therapie von Rotatorenmanschettendefekten. Berlin/Boston : Walter de Gruyter GmbH, 2019, S. 155-183

Wissenschaftliche Artikel

1. Behrend H, Zdravkovic V, Bösch M, Hochreiter B. No difference in joint awareness after TKA: a matched-pair analysis of a classic implant and its evolutional design. *Knee Surg Sports Traumatol Arthrosc* 2019; 27:2124-2129.
2. Calek A-K. Lipoma arborescens als Ursache von Knieschmerzen. *Swiss Medical Forum* 2019; 19:756-758.
3. Egidy C C, Cross M B, Nam D, Figgie M P, Jost B. Total Elbow Arthroplasty: Outcomes Driving the Evolution of Implant Design. *JBJS Rev* 2019; 7:e8.
4. Hasler A, Boyce G, Schallberger A, Jost B, Catanzaro S, Gerber C. Arthroscopic repair of isolated subscapularis tears: clinical outcome and structural integrity with a minimum follow-up of 4.6 years. *J Shoulder Elbow Surg* 2019; 28:2171-2180.
5. Hess S, Moser L B, Amsler F, Behrend H, Hirschmann M T. Highly variable coronal tibial and femoral alignment in osteoarthritic knees: a systematic review. *Knee Surg Sports Traumatol Arthrosc* 2019; 27:1368-1377.
6. Hirschmann M T, Hess S, Behrend H, Amsler F, Leclercq V, Moser L B. Phenotyping of hip-knee-ankle angle in young non-osteoarthritic knees provides better understanding of native alignment variability. *Knee Surg Sports Traumatol Arthrosc* 2019; 27:1378-1384.
7. Hirschmann M T, Moser L B, Amsler F, Behrend H, Leclercq V, Hess S. Phenotyping the knee in young non-osteoarthritic knees shows a wide distribution of femoral and tibial coronal alignment. *Knee Surg Sports Traumatol Arthrosc* 2019; 27:1385-1393.
8. Hirschmann M T, Moser L B, Amsler F, Behrend H, Leclercq V, Hess S. Functional knee phenotypes: a novel classification for phenotyping the coronal lower limb alignment based on the native alignment in young non-osteoarthritic patients. *Knee Surg Sports Traumatol Arthrosc* 2019; 27:1394-1402.
9. Hochreiter B, Hess S, Moser L, Hirschmann M T, Amsler F, Behrend H. Healthy knees have a highly variable patellofemoral alignment: a systematic review. *Knee Surg Sports Traumatol Arthrosc* 2019;.
10. Hochreiter B, Hess S, Moser L, Hirschmann M T, Amsler F, Behrend H. Correction to: Healthy knees have a highly variable patellofemoral alignment: a systematic review. *Knee Surg Sports Traumatol Arthrosc* 2019;.
11. Jacxsens M, Schmid J, Zdravkovic V, Jost B, Spross C. Is serial radiological evaluation of one-part proximal humeral fractures necessary. *Bone Joint J* 2019; 101-B:1307-1312.
12. Lotz H, Strahm C, Zdravkovic V, Jost B, Albrich W. Septic arthritis due to streptococci and enterococci in native joints. *Infection* 2019; 47:761-770.

13. Moser L B, Hess S, Amsler F, Behrend H, Hirschmann M T. Native non-osteoarthritic knees have a highly variable coronal alignment: a systematic review. *Knee Surg Sports Traumatol Arthrosc* 2019; 27:1359-1367.
14. Potocnik P, Hochreiter B, Harrasser N, Meester J, Toepfer A. Differenzialdiagnose des Fersenschmerzes. *Der Orthopäde* 2019; 48:261-280.
15. Potocnik P. Delayed diagnosis and successful interdisciplinary treatment of a pleomorphic leiomyosarcoma of the ankle. *FussSprung* 2019;.
16. Puskas G, Hochreiter B. Steifer Ellenbogen : Chirurgische Techniken der offenen Arthrolyse. *Arthroskopie* 2019; 32:256-262.
17. Spross C, Behrens G, Dietrich T J, Olaf Kim C H, Puskas G, Zdravkovic V, Jost B. Early Arthroscopic Repair of Acute Traumatic Massive Rotator Cuff Tears Leads to Reliable Reversal of Pseudoparesis: Clinical and Radiographic Outcome. *Arthroscopy* 2019;.
18. Spross C, Meester J, Mazzucchelli R A, Puskas G, Zdravkovic V, Jost B. Evidence-based algorithm to treat patients with proximal humerus fractures-a prospective study with early clinical and overall performance results. *J Shoulder Elbow Surg* 2019;.
19. Toepfer A, Keller S, Meester J. Die juvenile Knochenzyste des Calcaneus. *OUP* 2019;107-113.
20. Toepfer A. Significant prevalence of peripheral artery disease in patients with disturbed wound healing following elective foot and ankle surgery: Results from the ABI-PRIORITY (ABI as a Predictor of Impaired wound healing after ORthopedic surgerY) tria. *Vascular Medicine* 2019;.
21. Toepfer A. Trampolinspringen: Spass haben - aber sicher!. *MMW Fortschritte der Medizin* 2019;19-19.

Klinik für Urologie

Wissenschaftliche Artikel

1. Abt D, Muellhaupt G, Mordasini L, Güsewell S, Markart S, Zumstein V, Kessler T, Schmid H P, Engeler D S, Hechelhammer L. Outcome prediction of prostatic artery embolization: post hoc analysis of a randomized, open-label, non-inferiority trial. *BJU Int* 2019; 124:134-44.
2. Abt D, Schmid H P, Muellhaupt G. Benignes Prostatasyndrom: Limitationen minimalinvasiver Therapien. *UroForum* 2019;27-31.
3. Abt D, Schmid H P, Muellhaupt G. Prostatic Artery Embolization: A Curse or a Blessing. *Eur Urol* 2019;.
4. Adam S, Diener E M, Schmid H P, Arndt V, and the PROCAS-study group (2019) . prostate cancer survivorship in Switzerland (PROCAS): study protocol of the Swiss multiregional cohort. *Schweizer Krebsbulletin* 2019;256-61.
5. Babst C, Piller A, Boesch J, Schmid H P. Testicular sarcoidosis. *Urol Case Rep* 2019; 17:109-10.
6. Betschart P, Babst C, Schmid S, Rothermundt C, Abt D, Schwab C, Gillessen Sommer S, Engeler D S, Klingbiel D, Schmid H P, Omlin A. Shared Decision-Making for Patients with Advanced Urological Malignancies: Evaluation of a Joint Urological-Oncological Clinic Model. *Oncol Res Treat* 2019; 42:366-374.
7. Betschart P, Pratsinis M, Muellhaupt G, Rechner R, Herrmann T R, Gratzke C, Schmid H P, Zumstein V, Abt D. Information on surgical treatment of benign prostatic hyperplasia on YouTube is highly biased and misleading. *BJU Int* 2019;.
8. Betschart P, Schmid H P. Schonende Behandlung der vergrößerten Prostata. *der informierte patient* 2019;13.

9. Betschart P, Staubli S E, Zumstein V, Babst C, Sauter R, Schmid H P, Abt D. Improving Patient Education Materials: A Practical Algorithm from Development to Validation. *Curr Urol* 2019; 13:64-69.
10. Betschart P, Staubli S, Zumstein V, Babst C, Sauter R, Schmid H P, Abt D. Entwicklung und Validierung einer Patientenbroschüre zur Harnleiterschienung. Weniger Morbidität durch bessere Information. *Urologik* 2019;35-7.
11. Betschart P, Staubli S, Zumstein V, Babst C, Sauter R, Schmid H P, Abt D. Improving Patient education materials: a practical algorithm from development to validation. *Curr Urol* 2019;64-9.
12. Betschart P, Zumstein V, Buhmann M, Albrich W, Nolte O, Güsowell S, Schmid H P, Ren Q, Abt D. Influence of biofilms on morbidity associated with short-term indwelling ureteral stents: a prospective observational study. *World J Urol* 2019;1703-11.
13. Betschart P, Zumstein V, Buhmann M, Altenried S, Babst C, Güsowell S, Schmid H P, Ren Q, Abt D. Morbidity associated with long term Double-J ureteral stenting: A prospective observational study. German Medicale Science, www.egms.de 2019;.
14. Betschart P, Zumstein V, Buhmann M, Altenried S, Babst C, Muellhaupt G, Güsowell S, Schmid H P, Ren Q, Abt D. Symptoms associated with long-term double-J ureteral stenting and influence of biofilms. *Urology* 2019;72-8.
15. Betschart P, Zumstein V, Jichlinski P, Hermann T, Knoll T, Engeler D S, Muellhaupt G, Schmid H P, Abt D. Spoilt for choice: a survey of current practices of surgical urinary stone treatment and adherence to evidence-based guidelines among Swiss urologists. *Urol Int* 2019;357-63.
16. Betschart P, Zumstein V, Jichlinski P, Hermann T, Knoll T, Engeler D S, Muellhaupt G, Schmid H P, Abt D. Spoilt for choice: a survey of current practices of surgical urinary stone treatment and adherence to evidence based guidelines amongst Swiss urologists. German Medicale Science, www.egms.de 2019;.
17. Buhmann M T, Abt D, Nolte O, Neu T R, Strempel S, Albrich W, Betschart P, Zumstein V, Neels A, Maniura-Weber K, Ren Q. Encrustations on ureteral stents from patients without urinary tract infection reveal distinct uotypes and a low bacterial load. *Microbiome* 2019; 7:60.
18. Cottrell A M, Schneider M P, Goonewardene S, Yuan Y, Baranowski A P, Engeler D S, Borovicka J, Dinis-Oliveira P, Elneil S, Hughes J, Messelink B J, de C Williams A C. Benefits and Harms of Electrical Neuromodulation for Chronic Pelvic Pain: A Systematic Review. *Eur Urol Focus* 2019;.
19. Gramann T, Schwab C, Zumstein V, Betschart P, Schmid H P, Engeler D S. TUR-B an der Seitenwand ohne Obturatoriusblock. Ein prospektiv randomisierter Vergleich der monopolaren versus bipolaren TUR-B bezüglich Stimulation des Nervus obturatorius. *Urol Nachrichten* 2019; 01/02.2018:12-3.
20. Hechelhammer L, Müllhaupt G, Mordasini L, Markart S, Güsowell S, Betschart P, Schmid H P, Engeler D S, Abt D. Predictability and Inducibility of Detachment of Prostatic Central Gland Tissue after Prostatic Artery Embolization: Post Hoc Analysis of a Randomized Controlled Trial. *J Vasc Interv Radiol* 2019; 30:217-224.
21. Kaplan S A. Re: In-Hospital Cost Analysis of Prostatic Artery Embolization Compared with Transurethral Resection of the Prostate: Post Hoc Analysis of a Randomized Controlled Trial. *J Urol* 2019; 203:6.
22. Lyatoshinsky P, Pratsinis M, Abt D, Schmid H P, Zumstein V, Betschart P. Readability Assessment of Commonly Used German Urological Questionnaires. *Curr Urol* 2019; 13:87-93.
23. Muellhaupt G, Hechelhammer L, Diener P, Engeler D S, Güsowell S, Schmid H P, Mordasini L, Abt D. Ejakulationsstörungen nach Embolisation der Prostata. Eine Neubeurteilung von zwei prospektiven klinischen Studien. *Urol Nachrichten* 2019; Kongressausgabe 2:19.

24. Muellhaupt G, Hechelhammer L, Diener P, Engeler D S, Güsewell S, Schmid H P, Mordasini L, Abt D. Ejaculatory disorders after prostatic artery embolization: a reassessment of two prospective clinical trials. *Urologe* 2019;35-6.
25. Muellhaupt G, Hechelhammer L, Diener P A, Engeler D S, Güsewell S, Schmid H P, Mordasini L, Abt D. Ejaculatory disorders after prostatic artery embolization: a reassessment of two prospective clinical trials. *World J Urol* 2019;.
26. Muellhaupt G, Hechelhammer L, Engeler D S, Güsewell S, Betschart P, Zumstein V, Kessler T, Schmid H P, Mordasini L, Abt D. In-hospital cost analysis of prostatic artery embolization compared with transurethral resection of the prostate: post hoc analysis of a randomized controlled trial. *BJU Int* 2019;1055-60.
27. Muellhaupt G, Hechelhammer L, Engeler D S, Güsewell S, Betschart P, Zumstein V, Kessler T, Schmid H P, Mordasini L, Abt D. Analyse der Hospitalisationskosten der Embolisationen der Prostata im Vergleich zur transurethralen Resektion der Prostata: Post-hoc-Analyse einer randomisierten kontrollierten Studie. German Medicale Science, www.egms.de 2019;.
28. Muellhaupt G, Hechelhammer L, Engeler D S, Güsewell S, Diener P, Schmid H P, Mordasini L, Abt D. Ejakulationsstörungen nach Embolisation der Prostata. Eine Neubeurteilung von zwei prospektiven klinischen Studien. German Medicale Science, www.egms.de 2019;.
29. Plas E, Schmid H P. Ageing Male - wann hilft Testosteronsubstitution? *Urol Prax* 2019;86-91.
30. Schmid H P, Hechelhammer L, Arbelaez E, Mordasini L, Abt D. Technik der arteriellen Prostataembolisation (PAE): Ein Leitfaden Schritt für Schritt. German Medicale Science, www.egms.de 2019;.
31. Schmid H P, Koehle O. Impotenz - Therapieoptionen 2019. *Urol Prax* 2019;66-7.
32. Schmid H P, Muellhaupt G. News-Screen Urologie. *Urol Prax* 2019;160-2.
33. Schmid H P, Rüesch P, Dahinden U, Schaffert R. Online-Tutorial statt gedruckte Broschüre: Informationen für Männer mit lokalisiertem Prostatakarzinom - eine Pilotserie. German Medicale Science, www.egms.de 2019;.
34. Schmid H P. Die Prostataembolisation: ein neuer Therapiestandard? *Spectrum Urol* 2019;7.
35. Schmid H P. Experts Lounge. Stellenwert von Enzalutamid beim metastasierten kastrationsresistenten Prostatakarzinom. Zeichnet sich ein Paradigmenwechsel ab? *Medical Tribune* 2019;4-5.
36. Schmid H P. Experts Lounge. Wenn Prostata und Blase nicht mehr richtig mitspielen wollen. Symptome zuordnen und umfassend therapieren. *Medical Tribune* 2019;10-1.
37. Schmid H P. News-Screen Urologie. *Urol Prax* 2019;115-6.
38. Schmid H P. Prostataembolisation: Teer- oder Schotterstrasse? *Kongresszeitung DGU* 2019;8.
39. Schmid H P. Ueberlebensvorteil durch Prostatektomie beim lokalisierten Prostatakarzinom. *infomed-screen* 2019;10.
40. Wiesmayr M, Muellhaupt G, Schmid H P, Koehle O. Urologie: Wie lautet Ihre Diagnose? *Praxis* 2019;591-2.
41. Zumstein V, Betschart P, Buhmann M T, Albrich W, Nolte O, Güsewell S, Engeler D S, Schmid H P, Ren Q, Abt D. Detection of microbial colonization of the urinary tract of patients prior to secondary ureterorenoscopy is highly variable between different types of assessment: results of a prospective observational study. *Biofouling* 2019;1-10.
42. Zumstein V, Betschart P, Vetterlein M, Kluth L, Hechelhammer L, Mordasini L, Engeler D S, Kessler T, Schmid H P, Abt D. Prostatic artery embolization versus standard surgical treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review

and metaanalysis. Eur Uro Focus 2019;1091-100.

43. Zumstein V, Dahlem R, Kluth L A, Rosenbaum C M, Maurer V, Bahassan O, Engel O, Fisch M, Vetterlein M W. A critical outcome analysis of Asopa single-stage dorsal inlay substitution urethroplasty for penile urethral stricture. World J Urol 2019;.
44. Zumstein V, Schmid H P, Abt D. Benignes Prostatasyndrom. PAE vs. Standardtherapie beim BPS - ein Update. UroForum 2019;33-4.

Augenklinik

Wissenschaftlicher Artikel/Review

1. Bentivoglio M, Valmaggia C, Scholl H P N , Guber J. Comparative study of endolaser versus cryocoagulation in vitrectomy for rhegmatogenous retinal detachment. BMC Ophthalmol. 2019; 19:96.
2. Blechschmidt T, Krumsiek M, Todorova M. Positive Effects of Acupuncture Benefiting Individuals with Flammer Syndrome and Patients with Associated Pathologies. Flammer Syndrome, Advances in Predictive, Preventive and Personalised Medicine 2019; 11:351-369.
3. Della Volpe Waizel M, Camenzind Zuche H , Müller U , Rickmann A , Scholl H P N , Todorova M. Metabolic monitoring of transcorneal electrical stimulation in retinitis pigmentosa. Graefe's Archive for Clinical and Experimental Ophthalmology 2019; 258:79-87.
4. Della Volpe Waizel M, Türksever C, Todorova M. Influence of cataract light scatters on retinal vessel oxygen saturation. Acta Ophthalmol 2019; 98:e56-e62.
5. Guber J, Bentivoglio M, Scholl H P N , Sturm V, Valmaggia C. Combined pars plana vitrectomy with phacoemulsification for rhegmatogenous retinal detachment repair. Clin Ophthalmol. 2019;1587-1591.
6. Guber J, Schawkat M, Lang C, Scholl H P N , Valmaggia C. How to Prevent Retinal Shift after Rhegmatogenous Retinal Detachment Repair: A Prospective, Randomized Study. Ophthalmol Retina. 2019; 3:417-421.
7. Guber J, Vieregge M, Scholl H P N , Valmaggia C. Long-term Outcome after Autologous Free Internal Limiting Membrane Flap for the Treatment of Refractory Macular Holes. Klin Monbl Augenheilkd. 2019; 236:1012-1015.
8. Habibi I , Falfouj Y , Todorova M, Wyrsch S , Vaclavik V , Helfenstein M , Turki A , El Matri K, El Matri L, Schorderet D F. Clinical and Genetic Findings of Autosomal Recessive Bestrophinopathy (ARB). Genes 2019; 10:1-17.
9. Lazdinyte S, Schorderet D F, Schaller A, Valmaggia C, Todorova M. Analysis of Inherited Optic Neuropathies. Klin Monbl Augenheilkd. 2019; 236:451-461.
10. Schawkat M, Valmaggia C, Lang C, Scholl H P N , Guber J. Multimodal imaging for detecting metamorphopsia after successful retinal detachment repair. Graefes Arch Clin Exp Ophthalmol. 2019; 258:57-61.
11. Schawkat M, Valmaggia C, Lang C, Scholl H P N , Harsum S, Guber I, Guber J. Influence of Postoperative Posture on Macular Slippage after Macula-Off Retinal Detachment: A Randomized Controlled Trial. Ophthalmol Ther. 2019;519-525.
12. Stefánsson E, Olafsdottir O, Eliasdottir T, Vehmeijer W, Einarsdottir A, Bek T, Torp T, Grauslund J, Eysteinsson T, Karlsson R, Van Keer K, Stalmans I, Vandewalle E, Todorova M, Hammer M, Garhöfer G, Schmetterer L, Šín M, Hardarson S. Retinal oximetry: Metabolic imaging for diseases of the retina and brain. Prog Retin Eye Res. 2019; 70:1-22.

Hals-Nasen-Ohrenklinik

Wissenschaftliche Artikel

1. Broglie M A, Dulguerov P, Henke G, Siano M, Putora P M, Simon C, Zwahlen D, Huber G, Ballerini G, Beffa L, Giger R, Rothschild S, Negri S V, Elicin O. A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study-Part 4 (Biomarkers). *Front Oncol* 2019; 9:1128.
2. Candreia C, Rosenfeld J, Veraguth D, Cao Van H, Jacot E, Stieger C. Aktualisierte Empfehlung zum Neugeborenen-Hörscreening in der Schweiz. *PAEDIATRICA* 2019;.
3. de Galiza Barbosa F, Riesterer O, Tanadini-Lang S, Stieb S, Studer G, Pruschy M, Huber G, Huellner M W, Stolzmann P, Veit-Haibach P. Evaluation of 18F-FDG PET/CT as an early imaging biomarker for response monitoring after radiochemotherapy using cetuximab in head and neck squamous cell carcinoma. *Head Neck* 2019; 42:163-170.
4. den Hollander J, Broglie M A, Henke G, Siano M, Putora P M, Simon C, Zwahlen D, Huber G, Ballerini G, Beffa L, Giger R, Rothschild S, Negri S V, Elicin O. A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study-Part 1 (Head and Neck Surgery). *Front Oncol* 2019; 9:1125.
5. Elicin O, Putora P M, Siano M, Broglie M A, Simon C, Zwahlen D, Huber G, Ballerini G, Beffa L, Giger R, Rothschild S, Negri S V, Dulguerov P, Henke G. A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study-Part 2 (Radiation Oncology). *Front Oncol* 2019; 9:1126.
6. Galovic M, Stauber A J, Leisi N, Krammer W, Brugger F, Vehoff J, Balcerak P, Müller A, Müller M, Rosenfeld J, Polymeris A, Thilemann S, De Marchis G M, Niemann T, Leifke M, Lyrer P, Saladin P, Kahles T, Nedeltchev K, Sarikaya H, Jung S, Fischer U, Manno C, Cereda C W, Sander J W, Tettenborn B, Weder B J, Stöckli S, Arnold M, Kägi G. Development and Validation of a Prognostic Model of Swallowing Recovery and Enteral Tube Feeding After Ischemic Stroke. *JAMA Neurol* 2019; 76:561-570.
7. Hunter B G, Tasman A J. Clarification of a Suspension Technique for Unstable Nasal Bones-Reply. *JAMA Facial Plast Surg* 2019;.
8. Hunter B G, Tasman A J. Suspension Technique for Unstable Nasal Bones. *JAMA Facial Plast Surg* 2019;.
9. Romer C A E, Broglie Daeppen M A, Mueller M, Huber G, Güsewell S, Stöckli S. Long-term speech and swallowing function after primary resection and sentinel node biopsy for early oral squamous cell carcinoma. *Oral Oncol* 2019; 89:127-132.
10. Rosenfeld J. Wenn der Bissen im Hals stecken bleibt. *Zeitlupe* 2019; April 2019:27.
11. Rupp N J, Umbricht C A, Pizzuto D A, Lenggenhager D, Töpfer A, Müller J, Mühlmattler U J, Ferraro D A, Messerli M, Morand G B, Huber G, Eberli D, Schibli R, Burger I A. First clinico-pathological evidence of a non PSMA-related uptake mechanism for Ga-PSMA-11 in salivary glands. *J Nucl Med* 2019;.
12. Schilling C, Stöckli S, Vigili M G, de Bree R, Lai S Y, Alvarez J, Christensen A, Cognetti D M, D'Cruz A K, Frerich B, Garrel R, Kohno N, Klop W M, Kerawala C, Lawson G, McMahon J, Sassoon I, Shaw R J, Tvedskov J F, von Buchwald C, McGurk M. Surgical consensus guidelines on sentinel node biopsy (SNB) in patients with oral cancer. *Head Neck* 2019; 41:2655-2664.
13. Siano M, Dulguerov P, Broglie M A, Henke G, Putora P M, Simon C, Zwahlen D, Huber G, Ballerini G, Beffa L, Giger R, Rothschild S, Negri S V, Elicin O. A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study-Part 3 (Medical Oncology). *Front Oncol* 2019; 9:1127.

14. Tasman A J. Replacement of the Nasal Dorsum with a Diced Cartilage Glue Graft. *Facial Plast Surg* 2019; 35:53-57.
15. Vital D, Ikenberg K, Moch H, Rössle M, Huber G. The expression of PD-L1 in salivary gland carcinomas. *Sci Rep* 2019; 9:12724.
16. Werner J, Hüllner M W, Rupp N J, Huber A M, Broglie M A, Huber G, Morand G B. Predictive Value of Pretherapeutic Maximum Standardized Uptake Value (Suv) In Laryngeal and Hypopharyngeal Cancer. *Sci Rep* 2019; 9:8972.

Neurochirurgie

Wissenschaftliche Artikel

1. Guenzle J, Garrelfs N W C, Goeldner J M, Weyerbrock A. Cyclooxygenase (COX) Inhibition by Acetyl Salicylic Acid (ASA) Enhances Antitumor Effects of Nitric Oxide in Glioblastoma In Vitro. *Mol Neurobiol* 2019;;
2. Hejrat N, Spieler D, Samuel R, Regli L, Weyerbrock A, Surbeck W. Conscious Experience and Psychological Consequences of Awake Craniotomy. *World Neurosurg* 2019;;
3. Herrlinger U, Tzarisidis T, Mack F, Steinbach J P, Schlegel U, Sabel M, Hau P, Kortmann R D, Krex D, Grauer O, Goldbrunner R, Schnell O, Bähr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyerbrock A, Renovanz M, Bullinger L, Galldiks N, Vajkoczy P, Misch M, Vatter H, Stuplich M, Schäfer N, Kebir S, Weller J, Schaub C, Stummer W, Tonn J C, Simon M, Keil V C, Nelles M, Urbach H, Coenen M, Wick W, Weller M, Fimmers R, Schmid M, Hattingen E, Pietsch T, Coch C, Glas M, Neurooncology Working Group of the German Cancer Society . Lomustine-temozolamide combination therapy versus standard temozolamide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. *Lancet* 2019; 393:678-688.
4. Maduri R, Starnoni D, Rocca A, Bervini D, Zumofen D W, Stienen M N, Schatlo B, Fung C, Robert T, Seule M A, Burkhardt J K, Maldaner N, Roethlisberger M, Blackham K A, Marbacher S, D'Alonzo D, Remonda L, Machi P, Gralla J, Bijlenga P, Saliou G, Ballabeni P, Levivier M, Messerer M, Daniel R T, Swiss SOS Group . Ruptured posterior circulation aneurysms: epidemiology, patterns of care, and outcomes from the Swiss SOS national registry. *Acta Neurochir (Wien)* 2019; 161:769-779.
5. Maldaner N, Desai A, Gautschi O P, Regli L, Ratliff J K, Park J, Stienen M N. Improving the Patient-Physician Relationship in the Digital Era - Transformation From Subjective Questionnaires Into Objective Real-Time and Patient-Specific Data Reporting Tools. *Neurospine* 2019; 16:712-714.
6. Maldaner N, Steinsiepe V K, Goldberg J, Fung C, Bervini D, May A, Bijlenga P, Schaller K, Roethlisberger M, Zumofen D W, D'Alonzo D, Marbacher S, Fandino J, Maduri R, Daniel R T, Burkhardt J K, Chiappini A, Robert T, Schatlo B, Seule M, Weyerbrock A, Regli L, Stienen M N, Swiss SOS Study Group . Patterns of care for ruptured aneurysms of the middle cerebral artery: analysis of a Swiss national database (Swiss SOS). *J Neurosurg* 2019;1-10.

Neurologie

Buch

1. Felbecker A ; Limmroth V ; Tettenborn B: ESSENTIALS Demenzerkrankungen: Das Wichtigste für Ärzte aller Fachrichtungen. Elsevier Essentials. 1. München, Deutschland : Urban&Fischer/Elsevier, 2019.- ISBN 978-3437212437

Wissenschaftliche Artikel

1. Beerle N, Hader C, Kleger G R, Kägi G, Vehoff J. Das reversible zerebrale Vasokonstriktionssyndrom. Swiss Medical Forum 2019; 19:232-236.
2. Dallmayer M, Li J, Ohmura S, Alba Rubio R, Baldauf M, Höltig T L B, Musa J, Knott M M L, Stein S, Cidre-Aranaz F, Wehweck F S, Romero-Pérez L, Gerke J S, Orth M F, Marchetto A, Kirchner T, Bach H, Sannino G, Grünewald T G P. Targeting the CALCB/RAMP1 axis inhibits growth of Ewing sarcoma. Cell Death Dis 2019; 10:116.
3. Gövert F, Becktepe J, Balint B, Rocchi L, Brugger F, Garrido A, Walter T, Hannah R, Rothwell J, Elble R, Deuschl G, Bhatia K. Temporal discrimination is altered in patients with isolated asymmetric and jerky upper limb tremor. Mov Disord 2019;:
4. Hundsberger T, Schoser B, Leupold D, Rösler K M, Putora P M. Comparison of recent pivotal recommendations for the diagnosis and treatment of late-onset Pompe disease using diagnostic nodes-the Pompe disease burden scale. J Neurol 2019; 266:2010-2017.
5. Lagler F B, Moder A, Rohrbach M, Hennermann J, Mengel E, Gökce S, Hundsberger T, Rösler K M, Karabul N, Huemer M. Extent, impact, and predictors of diagnostic delay in Pompe disease: A combined survey approach to unveil the diagnostic odyssey. JIMD Rep 2019; 49:89-95.
6. Muehlemann N, Jouanetton B, de Léotoing L, Chalé J J, Fernandes J, Kägi G, Sarikaya H, Arnold M. Hospital costs impact of post ischemic stroke dysphagia: Database analyses of hospital discharges in France and Switzerland. PLoS ONE 2019; 14:e0210313.
7. Müller S, Vehoff J. Aktuelle Therapien der Multiplen Sklerose. der informierte @rzt 2019; Vol. 9:26-27.
8. Musa J, Cidre-Aranaz F, Aynaud M M, Orth M F, Knott M M L, Mirabeau O, Mazor G, Varon M, Höltig T L B, Grossetête S, Gartlgruber M, Surdez D, Gerke J S, Ohmura S, Marchetto A, Dallmayer M, Baldauf M, Stein S, Sannino G, Li J, Romero-Pérez L, Westermann F, Hartmann W, Dirksen U, Gymrek M, Anderson N D, Shlien A, Rotblat B, Kirchner T, Delattre O, Grünewald T G P. Cooperation of cancer drivers with regulatory germline variants shapes clinical outcomes. Nat Commun 2019; 10:4128.
9. Panje C, Putora P M, Hundsberger T, Hottinger A F, Roelcke U, Pesce G, Herrmann E, Matter-Walstra K. Impact of treatment decision algorithms on treatment costs in recurrent glioblastoma: a health economic study. Swiss Med Wkly 2019; 149:w20153.
10. Schneider T, Buckingham G, Hermsdörfer J. Torque-planning errors affect the perception of object properties and sensorimotor memories during object manipulation in uncertain grasp situations. J Neurophysiol 2019; 121:1289-1299.
11. Stark R S, Walch J, Kägi G. The Phenotypic Variation of a Family and the Role of Heterozygosity. Mov Disord Clin Pract 2019; 6:700-703.
12. Velicky M, Fluri F. Fortschritte in der Therapie des akuten ischämischen Schlaganfalls: Progrès dans le traitement de l'AVC ischémique aigu. Physioactive 2019;5-9.
1. Walch J. The phenotypic variation of a PARK-Parkin family and the role of heterozygosity. Movement Disorders Clinical Practice 2019; 2019 Sep:700-703.

Pathologie

Wissenschaftliche Artikel

1. Amary F, Markert E, Berisha F, Ye H, Gerrand C, Cool P, Tirabosco R, Lindsay D, Pillay N, O'Donnell P, Baumhoer D, Flanagan A M. FOS Expression in Osteoid Osteoma and Osteoblastoma: A Valuable Ancillary Diagnostic Tool. *Am J Surg Pathol* 2019; 43:1661-1667.
2. Anthis A H C, Tsolaki E, Didierlaurent L, Staubli S, Zboray R, Neels A, Dietrich D, Manser P, Desbiolles L M, Leschka S, Wildermuth S, Lehner S, Chavatte-Palmer P, Jochum W, Wick P, Dommann A, Bürki-Turnherr T, Fischer T, Hornung R, Bertazzo S, Herrmann I K. Nano-analytical characterization of endogenous minerals in healthy placental tissue: mineral distribution, composition and ultrastructure. *Analyst* 2019; 144:6850-6857.
3. Baumeler S, Jochum W, Neuweiler J, Bergamin I, Semela D. Controlled attenuation parameter for the assessment of liver steatosis in comparison with liver histology: a single-centre real life experience. *Swiss Med Wkly* 2019; 149:w20077.
4. Fehr M, Cathomas G, Graber A, Markert E, Gaus E, Boggian K. Multi-fungal sepsis and mucormycosis of the central nervous system in a patient treated with ibrutinib, a case report and review of the literature. *Med Mycol Case Rep* 2019; 27:14-16.
5. Frese J, Kettwig M, Zappel H, Hofer J, Gröne H J, Nagel M, Sunder-Plassmann G, Kain R, Neuweiler J, Gross O. Kidney Injury by Variants in the Gene Aggravated by Polymorphisms in Slit Diaphragm Genes Causes Focal Segmental Glomerulosclerosis. *Int J Mol Sci* 2019; 20:..
6. Hartmann S, Plütschow A, Mottok A, Bernd H W, Feller A C, Ott G, Cogliatti S B, Fend F, Quintanilla-Martinez L, Stein H, Klapper W, Möller P, Rosenwald A, Engert A, Hansmann M L, Eichenauer D A. The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphoma. *Am J Hematol* 2019; 94:1208-1213.
7. Loeffler-Wirth H, Kreuz M, Hopp L, Arakelyan A, Haake A, Cogliatti S B, Feller A C, Hansmann M L, Lenze D, Möller P, Müller-Hermelink H K, Fortenbacher E, Willscher E, Ott G, Rosenwald A, Pott C, Schwaenen C, Trautmann H, Wessendorf S, Stein H, Szczepanowski M, Trümper L, Hummel M, Klapper W, Siebert R, Loeffler M, Binder H, German Cancer Aid consortium Molecular Mechanisms for Malignant Lymphoma . A modular transcriptome map of mature B cell lymphomas. *Genome Med* 2019; 11:27.
8. Muellhaupt G, Hechelhammer L, Diener P A, Engeler D S, Güsewell S, Schmid H P, Mordasini L, Abt D. Ejaculatory disorders after prostatic artery embolization: a reassessment of two prospective clinical trials. *World J Urol* 2019; ..
9. O'Brien O, Wright M C, O'Brien C, Geoghegan O, Leonard N, Nicholson S, Cuffe S, Fabre A, Jochum W, Joerger M, Gray S G, Finn S P. Cost-Efficient and Easy to Perform PCR-Based Assay to Identify Met Exon 14 Skipping in Formalin-Fixed Paraffin-Embedded (FFPE) Non-Small Cell Lung Cancer (NSCLC) Samples. *Diagnostics (Basel)* 2019; 9:..
10. Savic S, Berezowska S, Eppenberger-Castori S, Cathomas G, Diebold J, Fleischmann A, Jochum W, Komminoth P, McKee T, Letovanec I, Jasarevic Z, Rössle M, Singer G, von Gunten M, Zettl A, Zweifel R, Soltermann A, Bubendorf L. PD-L1 testing of non-small cell lung cancer using different antibodies and platforms: a Swiss cross-validation study. *Virchows Arch* 2019; 475:67-76.
11. Schmid S, Klingbiel D, Aepli S, Britschgi C, Gautschi O, Pless M, Rothschild S, Wannesson L, Janthur W, Foerbs D, Demmer I, Jochum W, Früh M. Patterns of progression on osimertinib in

EGFR T790M positive NSCLC: A Swiss cohort study. Lung Cancer 2019; 130:149-155.

12. Varga Z, Li Q, Jochum W, Perriard U, Rau T, Tille J C, Hawle H, Klingbiel D, Thürlimann B, Ruhstaller T. Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort. Sci Rep 2019; 9:13534.
13. Zhu Y, Weiss T, Zhang Q, Sun R, Wang B, Yi X, Wu Z, Gao H, Cai X, Ruan G, Zhu T, Xu C, Lou S, Yu X, Gillet L, Blattmann P, Saba K, Fankhauser C D, Schmid M, Rutishauser D, Ljubicic J, Christiansen A, Fritz C, Rupp N J, Poyet C, Rushing E, Weller M, Roth P, Haralambieva E, Hofer S, Chen C, Jochum W, Gao X, Teng X, Chen L, Zhong Q, Wild P J, Aebersold R, Guo T. High-throughput proteomic analysis of FFPE tissue samples facilitates tumor stratification. Mol Oncol 2019; 13:2305-2328.

Radiologie und Nuklearmedizin

Wissenschaftliche Artikel

1. Kratochwil C, Fendler W P, Eiber M, Baum R, Bozkurt M F, Czernin J, Delgado Bolton R C, Ezziddin S, Forrer F, Hicks R J, Hope T A, Kabasakal L, Konijnenberg M, Kopka K, Lassmann M, Mottaghy F M, Oyen W, Rahbar K, Schöder H, Virgolini I, Wester H J, Bodei L, Fanti S, Haberkorn U, Herrmann K. EANM procedure guidelines for radionuclide therapy with Lu-labelled PSMA-ligands (Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging 2019; 46:2536-2544.
2. Weikert T, Maas O, Haas T, Klarhöfer M, Bremerich J, Forrer F, Sauter A W, Sommer G. Early Prediction of Treatment Response of Neuroendocrine Hepatic Metastases after Peptide Receptor Radionuclide Therapy with Y-DOTATOC Using Diffusion Weighted and Dynamic Contrast-Enhanced MRI. Contrast Media Mol Imaging 2019; 2019:1517208.
3. Abt D, Muellhaupt G, Mordasini L, Güsewell S, Markart S, Zumstein V, Kessler T, Schmid H P, Engeler D S, Hechelhammer L. Outcome prediction of prostatic artery embolization: post hoc analysis of a randomized, open-label, non-inferiority trial. BJU Int 2019; 124:134-44.
4. Anthis A H C, Tsolaki E, Didierlaurent L, Staubli S, Zboray R, Neels A, Dietrich D, Manser P, Desbiolles L M, Leschka S, Wildermuth S, Lehner S, Chavatte-Palmer P, Jochum W, Wick P, Dommann A, Bürki-Turnherr T, Fischer T, Hornung R, Bertazzo S, Herrmann I K. Nano-analytical characterization of endogenous minerals in healthy placental tissue: mineral distribution, composition and ultrastructure. Analyst 2019; 144:6850-6857.
5. Beerle N, Hader C, Kleger G R, Kägi G, Vehoff J. Das reversible zerebrale Vasokonstriktionssyndrom. Swiss Medical Forum 2019; 19:232-236.
6. den Hollander J, Broglie M A, Henke G, Siano M, Putora P M, Simon C, Zwahlen D, Huber G, Ballerini G, Beffa L, Giger R, Rothschild S, Negri S V, Elicin O. A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study-Part 1 (Head and Neck Surgery). Front Oncol 2019; 9:1125.
7. Haase R, Schlattmann P, Gueret P, Andreini D, Pontone G, Alkadhi H, Hausleiter J, Garcia M J, Leschka S, Meijboom W B, Zimmermann E, Gerber B, Schoepf U J, Shabestari A A, Nørgaard B L, Meijs M F L, Sato A, Ovrehus K A, Diederichsen A C P, Jenkins S M M, Knuuti J, Hamdan A, Halvorsen B A, Mendoza-Rodriguez V, Rochitte C E, Rixe J, Wan Y L, Langer C, Bettencourt N, Martuscelli E, Ghostine S, Buechel R R, Nikolaou K, Mickley H, Yang L, Zhang Z, Chen M Y, Halon D A, Rief M, Sun K, Hirt-Moch B, Niinuma H, Marcus R P, Muraglia S, Jakamy R, Chow B J, Kaufmann P A, Tardif J C, Nomura C, Kofoed K F, Laissy J P, Arbab-Zadeh A, Kitagawa K, Laham R, Jinzaki M, Hoe J, Rybicki F J, Scholte A, Paul N, Tan S Y, Yoshioka K, Röhle R, Schuetz G M, Schueler S, Coenen M H, Wieske V, Achenbach S, Budoff M J, Laule M, Newby D E, Dewey M, COME-CCT Consortium . Diagnosis of obstructive coronary artery disease using computed tomography angiography in patients with stable chest pain depending on clinical

probability and in clinically important subgroups: meta-analysis of individual patient data. BMJ 2019; 365:i1945.

8. Hechelhammer L, Muellhaupt G, Mordasini L, Markart S, Güsewell S, Betschart P, Schmid H P, Engeler D S, Abt D. Predictability and inducibility of detachment of prostatic central gland tissue after prostatic artery embolization: post hoc analysis of a randomized controlled trial. J Vasc Interv Radiol 2019;217-24.
9. Martini K, Ottlinger T, Serrallach B, Markart S, Glaser-Gallion N, Blüthgen C, Leschka S, Bauer R, Wildermuth S, Messerli M. Lung cancer screening with submillisievert chest CT: Potential pitfalls of pulmonary findings in different readers with various experience levels. Eur J Radiol 2019; 121:108720.
10. Messerli-Odermatt O, Serrallach B, Gubser M, Leschka S, Bauer R, Dubois J, Alkadhi H, Wildermuth S, Waelti S L. Chest X-ray Dose Equivalent Low-dose CT with Tin Filtration: Potential Role for the Assessment of Pectus Excavatum. Acad Radiol 2019;.
11. Muellhaupt G, Hechelhammer L, Diener P, Engeler D S, Güsewell S, Schmid H P, Mordasini L, Abt D. Ejakulationsstörungen nach Embolisation der Prostata. Eine Neubeurteilung von zwei prospektiven klinischen Studien. Urol Nachrichten 2019; Kongressausgabe 2:19.
12. Muellhaupt G, Hechelhammer L, Diener P, Engeler D S, Güsewell S, Schmid H P, Mordasini L, Abt D. Ejaculatory disorders after prostatic artery embolization: a reassessment of two prospective clinical trials. Urologe 2019;35-6.
13. Muellhaupt G, Hechelhammer L, Diener P A, Engeler D S, Güsewell S, Schmid H P, Mordasini L, Abt D. Ejaculatory disorders after prostatic artery embolization: a reassessment of two prospective clinical trials. World J Urol 2019;.
14. Muellhaupt G, Hechelhammer L, Engeler D S, Güsewell S, Betschart P, Zumstein V, Kessler T, Schmid H P, Mordasini L, Abt D. Analyse der Hospitalisationskosten der Embolisationen der Prostata im Vergleich zur transurethralen Resektion der Prostata: Post-hoc-Analyse einer randomisierten kontrollierten Studie. German Medicale Science, www.egms.de 2019;.
15. Muellhaupt G, Hechelhammer L, Engeler D S, Güsewell S, Betschart P, Zumstein V, Kessler T, Schmid H P, Mordasini L, Abt D. In-hospital cost analysis of prostatic artery embolization compared with transurethral resection of the prostate: post hoc analysis of a randomized controlled trial. BJU Int 2019;1055-60.
16. Muellhaupt G, Hechelhammer L, Engeler D S, Güsewell S, Diener P, Schmid H P, Mordasini L, Abt D. Ejakulationsstörungen nach Embolisation der Prostata. Eine Neubeurteilung von zwei prospektiven klinischen Studien. German Medicale Science, www.egms.de 2019;.
17. Neurauter E, Leschka S, Wildermuth S, Ehl N, Jörg L, Rickli H, Maeder M T. Use of coronary computed tomography angiography in clinical practice - single centre experience in Switzerland in light of current recommendations based on pretest probability considerations. Swiss Med Wkly 2019; 149:w20010.
18. Schmid H P, Hechelhammer L, Arbelaez E, Mordasini L, Abt D. Technik der arteriellen Prostataembolisation (PAE): Ein Leitfaden Schritt für Schritt. German Medicale Science, www.egms.de 2019;.
19. Weiss A, den Hollander J, Pietsch U. Transient Cortical Blindness: a Rare Complication After Cerebral Digital Subtraction Angiography. SN Comprehensive Clinical Medicine 2019; 1:567-570.
20. Zumstein V, Betschart P, Vetterlein M, Kluth L, Hechelhammer L, Mordasini L, Engeler D S, Kessler T, Schmid H P, Abt D. Prostatic artery embolization versus standard surgical treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and metaanalysis. Eur Uro Focus 2019;1091-100.

Radio-Onkologie

Wissenschaftliche Artikel

1. Bhaduri A, Insinga R, Guggisberg P, Panje C, Schwenkglenks M. Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland. *Swiss Med Wkly* 2019; 149:w20170.
2. Broglie M A, Dulguerov P, Henke G, Siano M, Putora P M, Simon C, Zwahlen D, Huber G, Ballerini G, Beffa L, Giger R, Rothschild S, Negri S V, Elicin O. A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study-Part 4 (Biomarkers). *Front Oncol* 2019; 9:1128.
3. den Hollander J, Broglie M A, Henke G, Siano M, Putora P M, Simon C, Zwahlen D, Huber G, Ballerini G, Beffa L, Giger R, Rothschild S, Negri S V, Elicin O. A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study-Part 1 (Head and Neck Surgery). *Front Oncol* 2019; 9:1125.
4. Elicin O, Putora P M, Siano M, Broglie M A, Simon C, Zwahlen D, Huber G, Ballerini G, Beffa L, Giger R, Rothschild S, Negri S V, Dulguerov P, Henke G. A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study-Part 2 (Radiation Oncology). *Front Oncol* 2019; 9:1126.
5. Garelli E, Rittmeyer A, Putora P M, Glatzer M, Dressel R, Andreas S. Abscopal effect in lung cancer: three case reports and a concise review. *Immunotherapy* 2019; 11:1445-1461.
6. Hundsberger T, Schoser B, Leupold D, Rösler K M, Putora P M. Comparison of recent pivotal recommendations for the diagnosis and treatment of late-onset Pompe disease using diagnostic nodes-the Pompe disease burden scale. *J Neurol* 2019; 266:2010-2017.
7. Iseli T, Plasswilm L. Radiotherapie bei schmerzhaften Metastasen : Konzept und Vorgehen in der klinischen Praxis. *Schweizerische Zeitschrift für Onkologie* 2019; 5:17-20.
8. Maas O, Forrer F, Maas M, Panje C, Blautzik J, Brühlmeier M, Engel-Bicik I, Giovanella L, Haldemann A, Kamel M E, Kneifel S, Rottenburger C, Schaefer N, Walter M A, Weidner S, Putora P M. Variations in radioiodine ablation: decision-making after total thyroidectomy. *Eur J Nucl Med Mol Imaging* 2019; ;
9. Panje C, Höng L, Hayoz S, Baracos V E, Herrmann E, Garcia Schüler H, Meier U R, Henke G, Schacher S, Hawle H, Gérard M A, Ruhstaller T, Plasswilm L, Swiss Group for Clinical Cancer Research (SAKK) . Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy. *Radiat Oncol* 2019; 14:166.
10. Panje C, Putora P M, Hundsberger T, Hottinger A F, Roelcke U, Pesce G, Herrmann E, Matter-Walstra K. Impact of treatment decision algorithms on treatment costs in recurrent glioblastoma: a health economic study. *Swiss Med Wkly* 2019; 149:w20153.
11. Panje C, Zilli T, Pra A D, Arnold W, Brouwer K, Garcia Schüler H I, Gomez S, Herrera F, Khanfir K, Papachristofilou A, Pesce G, Reuter C, Vees H, Zwahlen D, Putora P M. Radiotherapy for pelvic nodal recurrences after radical prostatectomy: patient selection in clinical practice. *Radiat Oncol* 2019; 14:177.
12. Plasswilm L, Studer G, Aebersold D M, Zwahlen D R. [Modern Treatment Concepts in Radiation Oncology]. *Ther Umsch* 2019; 76:209-218.
13. Putora P M, De Ruysscher D, Glatzer M, Widder J, Van Houtte P, Troost E G C, Slotman B J, Ramella S, Pöttgen C, Peeters S, Nestle U, McDonald F, Le Pechoux C, Dziadziuszko R, Belderbos J, Faivre-Finn C. The role of postoperative thoracic radiotherapy and prophylactic

cranial irradiation in early stage small cell lung cancer: Patient selection among ESTRO experts. Radiother Oncol 2019; 145:45-48.

14. Putora P M, Glatzer M, Belderbos J, Besse B, Blackhall F, Califano R, Cappuzzo F, de Marinis F, Dziadziuszko R, Felip E, Faivre-Finn C, Früh M, Garrido P, Le Pechoux C, McDonald F, Nestle U, Novello S, O'Brien M, Paz Ares L, Peeters S, Pöttgen C, Ramella S, Reck M, Slotman B, Troost E G C, Van Houtte P, Westeel V, Widder J, Mornex F, De Ruysscher D. Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. Radiother Oncol 2019; 133:163-166.
15. Putora P M, Glatzer M, De Ruysscher D, Faivre-Finn C, Belderbos J, Besse B, Blackhall F, Califano R, Cappuzzo F, de Marinis F, Dziadziuszko R, Felip E, Früh M, Garrido P, Le Pechoux C, McDonald F, Nestle U, Novello S, Brien M O, Paz Ares L, Peeters S, Pöttgen C, Ramella S, Reck M, Troost E G C, Van Houtte P, Westeel V, Widder J, Mornex F, Slotman B J. Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. Radiother Oncol 2019; 135:74-77.
16. Putora P M, Glatzer M, De Ruysscher D, Faivre-Finn C, Belderbos J, Besse B, Blackhall F, Califano R, Cappuzzo F, de Marinis F, Dziadziuszko R, Felip E, Früh M, Garrido P, Le Pechoux C, McDonald F, Nestle U, Novello S, O' Brien M, Paz Ares L, Peeters S, Pöttgen C, Ramella S, Reck M, Troost E G C, Van Houtte P, Westeel V, Widder J, Mornex F, Slotman B J. Erratum to "Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts" [Radiother. Oncol. 135 (2019) 74-77]. Radiother Oncol 2019; 141:332.
17. Putora P M. Decision Making in Oncology. JCO Clin Cancer Inform 2019; 3:1-2.
18. Riesterer O, Ciernik I F, Stahel R A, Xyrafas A, Aebersold D M, Plasswilm L, Mahmut Ozsahin E, Zwahlen D R, Nackaerts K, Zimmermann F, Sabrina Stark L, Weder W, Krayenbuehl J, Swiss Group for Clinical Cancer Research (SAKK) . Pattern of failure after adjuvant radiotherapy following extrapleural pneumonectomy of pleural mesothelioma in the SAKK 17/04 trial. Radiother Oncol 2019; 138:121-125.
19. Scheithauer W, Putora P M, Grünberger B, Eisterer W, Wöll E, Prager G, Schaberl-Moser R, Greil R, Glatzer M. Patterns of care in metastatic pancreatic cancer: patient selection in clinical routine. Therap Adv Gastroenterol 2019; 12:1756284819877635.
20. Schlachter M, Raidou R, Muren L, Preim B, Putora P M, Bühler K. State-of-the-Art Report: Visual Computing in Radiation Therapy Planning. Computer Graphics Forum 2019;753-779.
21. Siano M, Dulguerov P, Broglie M A, Henke G, Putora P M, Simon C, Zwahlen D, Huber G, Ballerini G, Beffa L, Giger R, Rothschild S, Negri S V, Elicin O. A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study-Part 3 (Medical Oncology). Front Oncol 2019; 9:1127.
22. Steffen T, Putora P M, Hübner M, Gloor B, Lehmann K, Kettelhack C, Adamina M, Peterli R, Schmidt J, Ris F, Glatzer M. Diagnostic Nodes of Patient Selection for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Among Colorectal Cancer Patients: A Swiss National Multicenter Survey. Clin Colorectal Cancer 2019; 18:e335-e342.

Rechtsmedizin

Wissenschaftliche Artikel

1. Grumann C, Huppertz L M, Bisel P, Angerer V, Auwärter V. Method validation and preliminary pharmacokinetic studies on the new designer stimulant 3-fluorophenmetrazine (3-FPM). Drug Testing and Analysis 2019; Epub ahead of print:.

-
2. Moosmann B, Bisel P, Westphal F, Wilde M, Kempf J, Angerer V, Auwärter V. Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines: An update comprising flunitrazepam, norflurazepam, and 4'-chlorodiazepam (Ro5-4864). Drug Test Anal 2019; 11:541-549.

Zentrale Notfallaufnahme

Wissenschaftliche Artikel

1. Bourgeois M, Carron P N, Ernst S, Exadaktylos A, Guigli Poretti M, Keller D, Meier K, Nickel C H, Rutschmann O T, Sieber R, Steuer S, Tabakovic S, Hugli O. Pain management policies and reported practices in Swiss emergency departments: a national survey. *Swiss Med Wkly* 2019; 149:w20155.
2. Minotti B, Batali A I, Sieber R. Woman With Painful Bowel Movements. *Ann Emerg Med* 2019; 74:e77-e78.
3. Minotti B, Blättler-Remund T, Sieber R, Tabakovic S. Nurse practitioners in emergency medicine: a Swiss perspective. *Eur J Emerg Med* 2019;
4. Minotti B, Pulver C, Schaub P, Sieber R, von Ow D, Leskow P. Pneumothorax, Chest Drain, and Commercial Air Travel. *Annals of emergency medicine* 2019; 73:551-552.
5. Saporito A, Aguirre J, Borgeat A, Perren A, Anselmi L, Poggi R, Minotti B, Cafarotti S, La Regina D, Ceruti S. Persistent postdischarge pain and chronic postoperative pain after breast cancer surgery under general anesthesia and single-shot paravertebral block: incidence, characteristics and impact on quality of life and healthcare costs. *Journal of Pain Research* 2019; 12:1193-1199.

Dermatologie/Allergologie

Wissenschaftliche Artikel

1. Ali O H, Bomze D, Ring S, Berner F, Fässler M, Diem S, Abdou M T, Hammers C, Emtenani S, Braun A, Cozzio A, Mani B, Jochum W, Schmidt E, Zillikens D, Sadik C D, Flatz L. BP180-specific IgG is associated with skin adverse events, therapy response and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors. *J Am Acad Dermatol* 2019;.
2. Berner F, Bomze D, Diem S, Ali O H, Fässler M, Ring S, Niederer R, Ackermann C J, Baumgaertner P, Pikor N, Cruz C G, van de Veen W, Akdis M, Nikolaev S, Läubli H, Zippelius A, Hartmann F, Cheng H W, Hönger G, Recher M, Goldman J, Cozzio A, Früh M, Neefjes J, Driessen C, Ludewig B, Hegazy A N, Jochum W, Speiser D E, Flatz L. Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer. *JAMA Oncol* 2019; 5:1043-1047.
3. Berner F, Bomze D, Flatz L. Immune-Related Adverse Events of Immune Checkpoint Inhibitors-From a Clinical to Pathophysiological View-In Reply. *JAMA Oncol* 2019;.
4. Bochem J, Zelba H, Amaral T, Spreuer J, Soffel D, Eigenthaler T, Wagner N, Uslu U, Terheyden P, Meier F, Garbe C, Pawelec G, Weide B, Wistuba-Hamprecht K. Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade. *PLoS ONE* 2019; 14:e0221301.
5. Bomze D, Hasan Ali O, Bate A, Flatz L. Association Between Immune-Related Adverse Events During Anti-PD-1 Therapy and Tumor Mutational Burden. *JAMA Oncol* 2019;.
6. Cazzaniga S, Anzengruber F, Augustin M, Boehncke W H, Borradori L, Conrad C, Cozzio A, Djamei V, French L E, Gilliet M, Häusermann P, Heidemeyer K, Itin P, Kolios A G A, Laffitte E, Maul J T, Mainetti C, Naldi L, Navarini A A, Rustenbach S J, Simon D, Sorbe C, Streit M, Yawalkar N. Linkage between patients' characteristics and prescribed systemic treatments for

psoriasis: a semantic connectivity map analysis of the Swiss Dermatology Network for Targeted Therapies registry. *J Eur Acad Dermatol Venereol* 2019; 33:2313-2318.

7. Diem S, Fässler M, Bomze D, Ali O H, Berner F, Niederer R, Hillmann D, Mangana J, Levesque M P, Dummer R, Risch L, Recher M, Risch M, Flatz L. Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment. *J Immunother* 2019; 42:89-93.
8. Fässler M, Diem S, Mangana J, Hasan Ali O, Berner F, Bomze D, Ring S, Niederer R, Gil Cruz C, Perez Shibayama C, Krolik M, Siano M, Joerger M, Recher M, Risch L, Güsewell S, Risch M, Speiser D E, Ludewig B, Levesque M P, Dummer R, Flatz L. Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients. *J Immunother Cancer* 2019; 7:50.
9. Gil Cruz C, Perez Shibayama C, De Martin A, Ronchi F, van der Borgh K, Niederer R, Onder L, Lütge M, Novkovic M, Nindl V, Ramos G, Arnoldini M, Slack E M C, Boivin-Jahns V, Jahns R, Wyss M, Mooser C, Lambrecht B N, Maeder M T, Rickli H, Flatz L, Eriksson U, Geuking M B, McCoy K D, Ludewig B. Microbiota-derived peptide mimics drive lethal inflammatory cardiomyopathy. *Science* 2019; 366:881-886.
10. Higgins R, Jensen A N, Wachstein J, Bruckner-Tuderman L, Spiegel R, Traber H, Achermann J, Schaller M, Fehrenbacher B, Röcken M, Ignatova D, Chang Y T, Fischer T, Schwieger-Briel A E, French L E, Hoetzenegger W, Hornung R, Malzacher A, Cozzio A, Navarini A, Has C, Guenova E. Uniparental Disomy of Chromosome 2 Unmasks New ITGA6 Recessive Mutation and Results in a Lethal Junctional Epidermolysis Bullosa in a Newborn. *Acta Derm Venereol* 2019; .
11. Isak V, Beerli T, Cozzio A, Flatz L. A Rare Case of Localized Argyria on the Face. *Case Rep Dermatol* 2019; 11:23-27.
12. Jonak C, Porkert S, Oerlemans S, Papadavid E, Molloy K, Lehner-Baumgartner E, Cozzio A, Efficace F, Scarisbrick J. Health-related Quality of Life in Cutaneous Lymphomas: Past, Present and Future. *Acta Derm Venereol* 2019; 99:640-646.
13. Maul J T, Navarini A A, Sommer R, Anzengruber F, Sorbe C, Mrowietz U, Drach M, Blome C, Boehncke W H, Thaci D, Reich K, von Kiedrowski R, Körber A, Yawalkar N, Mainetti C, Laffit E, Streit M, Rustenbach S, Conrad C, Borradori L, Gilliet M, Cozzio A, Itin P, Häusermann P, French L E, Radtke M A, Augustin M. Gender and age significantly determine patient needs and treatment goals in psoriasis - a lesson for practice. *J Eur Acad Dermatol Venereol* 2019; 33:700-708.
14. Saulite I, Hötzenecker W, Cozzio A. [Warning symptoms skin: cutaneous manifestation of drug allergy]. *Ther Umsch* 2019; 75:43-48.
15. Trefny M P, Rothschild S I, Uhlenbrock F, Rieder D, Kasenda B, Stanczak M A, Berner F, Kashyap A S, Kaiser M, Herzig P, Poechtrager S, Thommen D S, Geier F, Savic S, Jermann P, Alborelli I, Schaub S, Stenner F, Früh M, Trajanoski Z, Flatz L, Mertz K D, Zippelius A, Läubli H. A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer. *Clin Cancer Res* 2019; 25:3026-3034.
16. Wagner N, Weide B, Gries M, Reith M, Tarnanidis K, Schuermans V, Kemper C, Kehrel C, Funder A, Lichtenberger R, Sucker A, Herpel E, Holland-Letz T, Schadendorf D, Garbe C, Umansky V, Utikal J, Gebhardt C. Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies. *J Immunother Cancer* 2019; 7:343.

Brustzentrum

Wissenschaftliche Artikel

1. Burstein H J, Curigliano G, Loibl S, Dubsky P, Gnant M, Poortmans P, Colleoni M, Denkert C, Piccart-Gebhart M, Regan M, Senn H J, Winer E P, Thürlimann B, Members of the St. Gallen International Consensus Panel on the Primary Therapy of Early Breast Cancer 2019 . Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol 2019; 30:1541-1557.
2. Curigliano G, Burstein H J, P Winer E, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan M M, Piccart-Gebhart M, Senn H J, Thürlimann B, Panel Members of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017 . De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 2019; 30:1181.
3. Denkert C, Budczies J, Regan M M, Loibl S, Dell'Orto P, von Minckwitz G, Mastropasqua M G, Solbach C, Thürlimann B, Mehta K, Blohmer J U, Colleoni M, Müller V, Klauschen F, Ataseven B, Engels K, Kammler R, Pfitzner B M, Dietel M, Fasching P A, Viale G. Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial. Breast Cancer Res Treat 2019; 176:557-568.
4. Gargiulo P, Dietrich D, Herrmann R, Bodoky G, Ruhstaller T, Scheithauer W, Glimelius B, Berardi S, Pignata S, Brauchli P. Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores. Ther Adv Med Oncol 2019; 11:1758835918818351.
5. Kensler K H, Regan M M, Heng Y J, Baker G M, Pyle M E, Schnitt S J, Hazra A, Kammler R, Thürlimann B, Colleoni M, Viale G, Brown M, Tamimi R M. Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98. Breast Cancer Res 2019; 21:30.
6. Mark M, Thürlimann B, Ribi K, Schär C, Dietrich D, Cathomas R, Zürcher-Härdi U, von Briel T, Anchisi S, Bohanes P, Blum V, von Burg P, Mannhart M, Caspar C B, von Moos R. Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16). J Bone Oncol 2019; 21:100273.
7. Panje C, Höng L, Hayoz S, Baracos V E, Herrmann E, Garcia Schüler H, Meier U R, Henke G, Schacher S, Hawle H, Gérard M A, Ruhstaller T, Plasswilm L, Swiss Group for Clinical Cancer Research (SAKK) . Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy. Radiat Oncol 2019; 14:166.
8. Schmid S, Klingbiel D, Aebi S, Goldhirsch A, Mamot C, Munzone E, Nolè F, Oehlschlegel C, Pagani O, Pestalozzi B, Rochlitz C, Thürlimann B, von Moos R, Weder P, Zaman K, Ruhstaller T. Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data. BMC Cancer 2019; 19:902.
9. Varga Z, Li Q, Jochum W, Perriard U, Rau T, Tille J C, Hawle H, Klingbiel D, Thürlimann B, Ruhstaller T. Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort. Sci Rep 2019; 9:13534.

Muskelzentrum/ALS clinic

Wissenschaftliche Artikel

1. Alix J J P, Neuwirth C, Gelder L, Burkhardt C, Castro J, de Carvalho M, Gawel M, Goedee S, Grosskreutz J, Lenglet T, Moglia C, Omer T, Schrooten M, Nandedkar S, Stålberg E, Barkhaus P E, Furtula J, van Dijk J P, Baldinger R, Costa J, Otto M, Sandberg A, Weber M. Assessment of the reliability of the motor unit size index (MUSIX) in single subject "round-robin" and multi-centre settings. *Clin Neurophysiol* 2019; 130:666-674.
2. Braun N. The revised El Escorial criteria "clinically probable laboratory supported ALS"—once a promising now a superfluous category. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration* 2019;.
3. Brenner D, Rosenbohm A, Yilmaz R, Müller K, Grehl T, Petri S, Meyer T, Grosskreutz J, Weydt P, Ruf W, Neuwirth C, Weber M, Pinto S, Claeys K G, Schrank B, Jordan B, Knehr A, Günther K, Hübers A, Zeller D, Kubisch C, Jablonka S, Sendtner M, Klopstock T, de Carvalho M, Sperfeld A, Borck G, Volk A E, Dorst J, Weis J, Otto M, Schuster J, Del Tredici K, Braak H, Danzer K M, Freischmidt A, Meitinger T, Ludolph A C, Andersen P M, Weishaupt J H, German ALS network MND-NET . Reply: Adult-onset distal spinal muscular atrophy: a new phenotype associated with KIF5A mutations. *Brain* 2019;.
4. Czell D, Neuwirth C, Weber M, Sartoretti-Schefer S, Gutzeit A, Reischauer C. Nine Hole Peg Test and Transcranial Magnetic Stimulation: Useful to Evaluate Dexterity of the Hand and Disease Progression in Amyotrophic Lateral Sclerosis. *Neurol Res Int* 2019; 2019:7397491.
5. Lingor P, Weber M, Camu W, Friede T, Hilgers R, Leha A, Neuwirth C, Günther R, Benatar M, Kuzma-Kozakiewicz M, Bidner H, Blankenstein C, Frontini R, Ludolph A, Koch J C, ROCK-ALS Investigators . ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis. *Front Neurol* 2019; 10:293.
6. Stålberg E, van Dijk H, Falck B, Kimura J, Neuwirth C, Pitt M, Podnar S, Rubin D I, Rutkove S, Sanders D B, Sonoo M, Tankisi H, Zwarts M. Standards for quantification of EMG and neurography. *Clin Neurophysiol* 2019;.

Institut für Immunbiologie

Wissenschaftliche Artikel

1. Argilaguet J, Pedragosa M, Esteve-Codina A, Riera G, Vidal E, Gil Cruz C, Casella V, Andreu D, Kaisho T, Bocharov G, Ludewig B, Heath S, Meyerhans A. Systems analysis reveals complex biological processes during virus infection fate decisions. *Genome Res* 2019; 29:907-919.
2. Berner F, Bomze D, Flatz L. Immune-Related Adverse Events of Immune Checkpoint Inhibitors- From a Clinical to Pathophysiological View-In Reply. *JAMA Oncol* 2019;.
3. Brenig R, Pop O, Triantafyllou E, Geng A, Singanayagam A, Perez Shibayama C, Besse L, Cupovic J, Künzler-Heule P, Boldanova T, Brand S, Semela D, Duong F H, Weston C J, Ludewig B, Heim M H, Wendon J, Antoniades C G, Bernsmeier C. Expression of AXL receptor tyrosine kinase relates to monocyte dysfunction and severity of cirrhosis. *Life Sci Alliance* 2019; 3:.
4. Camara A, Cordeiro O G, Alloush F, Sponsel J, Chypre M, Onder L, Asano K, Tanaka M, Yagita H, Ludewig B, Flacher V, Mueller C G. Lymph Node Mesenchymal and Endothelial Stromal Cells Cooperate via the RANK-RANKL Cytokine Axis to Shape the Sinusoidal Macrophage Niche. *Immunity* 2019; 50:1467-1481.e6.
5. Cheng H W, Onder L, Novkovic M, Soneson C, Lütge M, Pikor N, Scandella E, Robinson M D, Miyazaki J I, Tersteegen A, Sorg U, Pfeffer K, Rülicke T, Hehlgans T, Ludewig B. Origin and

differentiation trajectories of fibroblastic reticular cells in the splenic white pulp. *Nat Commun* 2019; 10:1739.

6. Colston J M, Hutchings C, Chinnakannan S, Highton A, Perez Shibayama C, Ludewig B, Klenerman P. Divergent memory responses driven by adenoviral vectors are impacted by epitope competition. *Eur J Immunol* 2019;:
7. Denton A E, Innocentin S, Carr E J, Bradford B M, Lafouresse F, Mabbott N A, Mörbe U, Ludewig B, Groom J R, Good-Jacobson K L, Linterman M A. Type I interferon induces CXCL13 to support ectopic germinal center formation. *J Exp Med* 2019;:
8. Diem S, Fässler M, Bomze D, Ali O H, Berner F, Niederer R, Hillmann D, Mangana J, Levesque M P, Dummer R, Risch L, Recher M, Risch M, Flatz L. Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment. *J Immunother* 2019; 42:89-93.
9. Dubey L K, Ludewig B, Luther S A, Harris N L. IL-4R α -Expressing B Cells Are Required for CXCL13 Production by Fibroblastic Reticular Cells. *Cell Rep* 2019; 27:2442-2458.e5.
10. Fässler M, Diem S, Mangana J, Hasan Ali O, Berner F, Bomze D, Ring S, Niederer R, Gil Cruz C, Perez Shibayama C, Krolik M, Siano M, Joerger M, Recher M, Risch L, Güsewell S, Risch M, Speiser D E, Ludewig B, Levesque M P, Dummer R, Flatz L. Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients. *J Immunother Cancer* 2019; 7:50.
11. Gil Cruz C, Perez Shibayama C, De Martin A, Ronchi F, van der Borgh K, Niederer R, Onder L, Lütge M, Novkovic M, Nindl V, Ramos G, Arnoldini M, Slack E M C, Boivin-Jahns V, Jahns R, Wyss M, Mooser C, Lambrecht B N, Maeder M T, Rickli H, Flatz L, Eriksson U, Geuking M B, McCoy K D, Ludewig B. Microbiota-derived peptide mimics drive lethal inflammatory cardiomyopathy. *Science* 2019; 366:881-886.
12. Lercher A, Bhattacharya A, Popa A M, Caldera M, Schlapansky M F, Baazim H, Agerer B, Gürtl B, Kosack L, Májek P, Brunner J S, Vitko D, Pinter T, Genger J W, Orlova A, Pikor N, Reil D, Ozsvár-Kozma M, Kalinke U, Ludewig B, Moriggl R, Bennett K L, Menche J, Cheng P N, Schabbauer G, Trauner M, Klavins K, Bergthaler A. Type I Interferon Signaling Disrupts the Hepatic Urea Cycle and Alters Systemic Metabolism to Suppress T Cell Function. *Immunity* 2019; 51:1074-1087.e9.
13. Li C, Lam E, Perez Shibayama C, Ward L A, Zhang J, Lee D, Nguyen A, Ahmed M, Brownlie E, Korneev K V, Rojas O, Sun T, Navarre W, He H H, Liao S, Martin A, Ludewig B, Gommerman J L. Early-life programming of mesenteric lymph node stromal cell identity by the lymphotoxin pathway regulates adult mucosal immunity. *Sci Immunol* 2019; 4:.
14. Ludewig B. Rolf Zinkernagel and the co-discovery of MHC restriction together with Peter Doherty. *Allergy* 2019;:
15. Perez Shibayama C, Gil Cruz C, Ludewig B. Fibroblastic reticular cells at the nexus of innate and adaptive immune responses. *Immunol Rev* 2019; 289:31-41.
16. Rieckmann M, Delgobo M, Gaal C, Büchner L, Steinau P, Reshef D, Gil Cruz C, Ter Horst E N, Kircher M, Reiter T, Heinze K G, Niessen H W, Krijnen P A, van der Laan A M, Piek J J, Koch C, Wester H J, Lapa C, Bauer W R, Ludewig B, Friedman N, Frantz S, Hofmann U, Ramos G C. Myocardial infarction triggers cardioprotective antigen-specific T helper cell responses. *J Clin Invest* 2019; 130:.
17. Solmaz G, Puttur F, Francozo M, Lindenberg M, Guderian M, Swallow M, Duhan V, Khairnar V, Kalinke U, Ludewig B, Clausen B E, Wagner H, Lang K S, Sparwasser T D. TLR7 Controls VSV Replication in CD169 SCS Macrophages and Associated Viral Neuroinvasion. *Front Immunol* 2019; 10:466.

18. Trefny M P, Rothschild S I, Uhlenbrock F, Rieder D, Kasenda B, Stanczak M A, Berner F, Kashyap A S, Kaiser M, Herzig P, Poechtrager S, Thommen D S, Geier F, Savic S, Jermann P, Alborelli I, Schaub S, Stenner F, Früh M, Trajanoski Z, Flatz L, Mertz K D, Zippelius A, Läubli H. A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer. *Clin Cancer Res* 2019; 25:3026-3034.
19. Zarak-Crnkovic M, Kania G, Jaźwa-Kusior A, Czepiel M, Wijnen W J, Czyż J, Müller-Edenborn B, Vdovenko D, Lindner D, Gil Cruz C, Bachmann M, Westermann D, Ludewig B, Distler O, Lüscher T F, Klingel K, Eriksson U, Błyszczuk P. Heart non-specific effector CD4 T cells protect from postinflammatory fibrosis and cardiac dysfunction in experimental autoimmune myocarditis. *Basic Res Cardiol* 2019; 115:6.

Clinical Trials Unit

Wissenschaftliche Artikel

1. Besse L, Besse A, Mendez-Lopez M, Vasickova K, Sedlackova M, Vanhara P, Kraus M, Bader J, Ferreira R B, Castellano R K, Law B K, Driessen C. A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis. *Haematologica* 2019; 104:e415-e419.
2. Betschart P, Staubli S E, Zumstein V, Babst C, Sauter R, Schmid H P, Abt D. Improving Patient Education Materials: A Practical Algorithm from Development to Validation. *Curr Urol* 2019; 13:64-69.
3. Brünnert D, Kraus M, Stühmer T, Kirner S, Heiden R, Goyal P, Driessen C, Bargou R C, Chatterjee M. Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma. *Biochim Biophys Acta Mol Basis Dis* 2019; 1865:1666-1676.
4. Fässler M, Diem S, Mangana J, Hasan Ali O, Berner F, Bomze D, Ring S, Niederer R, Gil Cruz C, Perez Shibayama C, Krolik M, Siano M, Joerger M, Recher M, Risch L, Güsewell S, Risch M, Speiser D E, Ludewig B, Levesque M P, Dummer R, Flatz L. Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients. *J Immunother Cancer* 2019; 7:50.
5. Hitz F, Kraus M, Pabst T, Hess D, Besse L, Silzle T, Novak U, Seipel K, Rondeau S, Stüdeli S, Vilei S B, Samaras P, Mey U, Driessen C, Swiss Group for Clinical Cancer Research SAKK . Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10). *Blood Cancer J* 2019; 9:70.
6. Muellhaupt G, Hechelhammer L, Diener P A, Engeler D S, Güsewell S, Schmid H P, Mordasini L, Abt D. Ejaculatory disorders after prostatic artery embolization: a reassessment of two prospective clinical trials. *World J Urol* 2019;.
7. Romer C A E, Broglie Daeppen M A, Mueller M, Huber G, Güsewell S, Stöckli S. Long-term speech and swallowing function after primary resection and sentinel node biopsy for early oral squamous cell carcinoma. *Oral Oncol* 2019; 89:127-132.
8. Zumstein V, Betschart P, Buhmann M T, Albrich W, Nolte O, Güsewell S, Engeler D S, Schmid H P, Ren Q, Abt D. Detection of microbial colonization of the urinary tract of patients prior to secondary ureterorenoscopy is highly variable between different types of assessment: results of a prospective observational study. *Biofouling* 2019;1-10.

Palliativzentrum

Wissenschaftliche Artikel

1. Renz M, Büche D, Reichmuth O, Schuett Mao M, Renz U, Siebenrock R, Strasser F. Forgiveness and Reconciliation Processes in Dying Patients With Cancer. *Am J Hosp Palliat Care* 2019;1049909119867675.
2. Stängle S, Schnepp W, Büche D, Fringer A. Long-term care nurses' attitudes and the incidence of voluntary stopping of eating and drinking: A cross-sectional study. *J Adv Nurs* 2019; 76:526-534.



Kompetent
Umfassend
Nah

Kontakt

Kantonsspital St.Gallen

Rorschacher Strasse 95
CH-9007 St.Gallen
Tel. +41 71 494 11 11

Spital Rorschach

Heidenerstrasse 11
CH-9400 Rorschach
Tel. +41 71 858 31 11

Spital Flawil

Krankenhausstrasse 23
CH-9230 Flawil
Tel. +41 71 394 71 11